Способ совместного культивирования зрелых адипоцитов с клетками крыс

Изобретение относится к области биохимии. Предложен способ совместного культивирования зрелых адипоцитов с клетками крыс. Способ включает выделение зрелых адипоцитов из жировой ткани крыс, получение в монокультуре монослоя прикрепленных к вкладышу адипоцитов, формирование слоя клеток крыс на дне сосуда, заполнение питательной средой всего объема данного сосуда и размещение вкладыша с монослоем адипоцитов поверх его. Изобретение обеспечивает однотипную локализацию адипоцитов в объеме культурального сосуда, а также возможность микроскопического наблюдения за состоянием всех клеточных популяций. 6 ил., 3 пр.

ВЫРАЩЕННЫЕ В ПРИКРЕПЛЕННОЙ К СУБСТРАТУ КУЛЬТУРЕ КЛЕТКИ ИЗ ТКАНИ ПЛАЦЕНТЫ И ИХ ИСПОЛЬЗОВАНИЕ ПРИ ЛЕЧЕНИИ

... 1. Способ культивирования выращенных в прикрепленной к субстрату культуре клеток из плаценты или жировой ткани, где способ включает культивирование выращенных в прикрепленной к субстрату культуре клеток из плаценты или жировой ткани в трехмерных (3D) условиях культивирования, которые обеспечивают возможность размножения клеток, причем указанные условия включают перфузию, где указанная перфузия регулируется в соответствии с концентрацией глюкозы культуральной среды. ! 2. Способ по п.1, где указанная культуральная среда меняется при указанной концентрации глюкозы примерно 550 мг/л. ! 3. Способ по п.1, где указанные 3D условия культивирования включают одно из: ! (i) культивирования указанной популяции выращенных в прикрепленной к субстрату культуре клеток в биореакторе, имеющем цилиндрический уплотненный слой, и культуральная среда течет через уплотненный слой; ! (ii) культивирования указанной популяции выращенных в прикрепленной к субстрату культуре клеток в фазе роста, поддерживая рабочий ...

Three dimensional cell culture

EQUIPMENT FOR THE PRODUCTION OF A FETTZELLENHALTIGEN COMPOSITION

PROCEDURE FOR THE USE OF FROM FATTY TISSUE COMING CELLS WITH THE TREATMENT OF HEART CYCLE SUFFERING

CELL RELEASE STENCILS

Adipose tissue matrices

The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular extracellular matrices. In addition, the present disclosure provides systems and methods for using such products.

Adipocyte culture

Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy

A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion.

METHODS AND COMPOSITIONS FOR PREVENTING OBESITY AND OBESITY RELATED DISORDERS

Methods for increasing thermogenic adipocytes

In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

ADIPOSE STROMAL STEM CELLS FOR TISSUE AND VASCULAR MODIFICATION

Compositions and methods for treating and preventing tissue injury and disease

The present invention provides novel compositions comprising multipotent ceils or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated virases, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes

Therapeutic methods

THERAPEUTIC METHODS Abstract Provided herein is a use of an adipose tissue-derived cell suspension which comprises adipocytes for the preparation of a pharmaceutical composition for use in the treatment of an inflammatory disorder, a cartilage or bone disorder and/or the alleviation 5 of pain associated with an inflammatory disorder in a mammalian subject. Also provided herein is a method of treating an inflammatory disorder, a cartilage or bone disorder or alleviating pain associated with an inflammatory disorder in a mammalian subject, comprising administering to the subject a pharmaceutical composition which comprises: (i) an adipose tissue-derived cell suspension which comprises adipocytes; or (ii) a cell 10 free extract which is prepared from an adipose tissue-derived cell suspension, wherein the adipose tissue-derived cell suspension comprises adipocytes, together with a pharmaceutically-acceptable carrier or diluent.

Composition for differentiation induction of adipocyte containing stem cell-derived exosome, regeneration of adipose tissue, and skin whitening or wrinkle improvement

The present invention relates to a pharmaceutical composition for adipocyte differentiation induction and/or adipose tissue regeneration comprising, as an active ingredient, an exosome extracted from a stem cell which is differentiating into an adipocyte. The exosome is excellent in expression rate of bioactive factors influencing the differentiation into an adipocyte and has the effect of differentiating a stem cell into an adipocyte. Accordingly, the present invention can be applied to differentiation inducing agents of a stem cell, injections for tissue regeneration, fillers for cosmetic purposes, preparations for tissue engineering, etc. The invention also relates to a cosmetic composition for skin whitening, wrinkle improvement and regeneration, containing an exosome extracted from a stem cell as an active ingredient. Since the exosome contains genes, proteins, growth factors etc. associated with the proliferation, differentiation, and regeneration of stem cells; is a purified component ...

Therapeutics using adipose cells and cell secretions

The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.

Adherent cells from placenta tissue and use thereof in therapy

Process and compositions for achieving mammalian energy balance

Disclosed is a method of achieving optimal mammalian energy balance using forskoin on a particular physiological and developmental stage of the mammalian cellular system. Page 1 of I ...

Therapeutics using adipose cells and cell secretions

The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.

Multipotent and immunocompatible stem cell concentrate

The present invention generally relates to a stem cell concentrate isolated from a mammalian vascularized adipose tissue, biopharmaceuticals containing such concentrate and use thereof in therapies for treating diseases in mammals.

Method for cultivating living cells, especially mature fat cells, which are prepared from tissue and float in liquids

PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD

... ²²²Human progenitor cells are extracted from Wharton's jelly that lies within a ²perivasculature zone of human umbilical cord. The progenitor cell population ²proliferates rapidly, and harbours both osteoprogenitor cells and MHC-/- ²cells, and is useful to grow and repair human tissues including bone.² ...

PRIMARY CULTURED ADIPOCYTES FOR GENE THERAPY

The present invention relates to primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells. This invention provides cells suitable for gene therapy, which can replace bone marrow cells and liver cells used for conventional ex vivo gene therapy. The present invention established methods for transferring foreign genes into primary cultured adipocytes, which are suitable for ex vivo gene therapy; can be easily collected and implanted; and can be removed after implantation. Specifically, the present invention established these methods that use retroviral vectors. The present invention also established primary cultured adipocytes for gene therapy, where the adipocytes stably maintain a foreign gene encoding a protein that is secreted outside of cells.

AUGMENTATION AND REPAIR OF AGE-RELATED SOFT TISSUE DEFECTS

The present invention discloses methods for the long-term augmentation and/or repair of skin defects (scars, skin laxness, skin thinning, and skin augmentation), cellulite, breast tissue, wounds and burns, urological and gastroesophageal sphincter structures, hernias, periodontal disease and disorders, tendon and ligament tears and baldness, by the injection or direct surgical placement/implantation of autologous cultured cells and/or cultured cell-produced extracellular matrix that is derived from connective tissue, dermis, fascia, lamina propria, stroma, adipose tissue, muscle, tendon, ligament or the hair follicle. The corrective application is done on tissue proximal or within the area of the defect. The method involves retrieving viable cells from the subject, a neonate or human fetus. Alternatively, the corrective application involves the cells placed in a matrix, preferably comprised of autologous extracellular matrix constituents as a three- dimensional structure or as a suspension ...

PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD

Human progenitor cells are extracted from Wharton's jelly that lies within a perivasculature zone of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours both osteoprogenitor cells and MHC-/- cells, and is useful to grow and repair human tissues including bone.

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING TISSUE INJURY AND DISEASE

The present invention provides novel compositions comprising multipotent ceils or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated virases, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.

DEVICE AND METHOD FOR PREPARING TISSUE, PARTICULARLY ADIPOSE TISSUE, FOR TRANSPLANTATION FROM LOBULAR FAT EXTRACTED BY LIPOSUCTION

A device and a method for preparing adipose tissue for transplantation from lobular fat extracted, for instance by liposuction, said fat consisting of a fluid component comprising an oily component, a blood component and/or sterile solutions and a solid component comprising cell fragments, cells and one or more cell macroagglomerates of heterogeneous size, wherein said device is composed of at least one washing and separating container (1) having a washing chamber (101) for washing the liposuctioned material, which container (1) has an inlet (102) and an outlet (103) for the liposuctioned material to enter the washing chamber (101) through the inlet (102) and for at least part of said material, particularly the fluid component, to exit said chamber (101) through the outlet (103), said washing chamber (101) including means for forming an emulsion of fluid components. A method of treating body and face volume deficiencies, improving skin trophism and/or for biological stimulation by the adipose ...

METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF AN ALLOGENIC CELL AND THERAPEUTIC USES

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.

USE OF ADIPOSE TISSUE-DERIVED STROMAL CELLS FOR CHONDROCYTE DIFFERENTIATION AND CARTILAGE REPAIR

Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is discloses.

Adeno-associated virus vectors, useful for transduction of the adipose tissue.

Die vorliegende Erfindung betrifft Adeno-assoziierte Virusvektoren, die für die Transduktion von Fettgewebe nützlich sind. Die Erfindung betrifft auch Polynukleotide, Plasmide, Vektoren und Verfahren zur Herstellung solcher Adeno-assoziierten Virusvektoren. Die Erfindung betrifft auch Gentherapieverfahren, die für die Behandlung von Erkrankungen nützlich sind, die die Regulierung der Expressionslevel eines Gens erfordern.

METHOD AND COMPOSITIONS FOR ACHIEVING ENERGY BALANCE IN MAMMALS

Dedifferentiated, programmable stem cells of monocytic origin, and their production and use

Using cells from white adipose tissue for reconstruction of vascular networks e.g. for treating complications of ischemic disease can differentiate into mature endothelial cells

Utilisation de cellules issues du tissu adipeux blanc médullaire ou extra-médullaire et notamment de la fraction stromale vasculaire extra-médullaire (FSV) et/ou d'adipocytes matures dédifférenciés quelle qu'en soit l'origine, pour induire la formation d'une vascularisation fonctionnelle.

세포, 핵산 작제물, 당해 작제물을 포함하는 세포 및 당해 세포를 질환 치료에 사용하는 방법

... 본 발명은 IDO를 발현할 수 있는 세포, IDO를 발현시키기 위한 핵산 작제물, 당해 작제물을 포함하는 세포, 및 당해 세포를 질환의 치료에 사용하는 방법에 관한 것이다. 특히, 본 발명은 INF-감마에 대한 노출의 부재하에 IDO를 발현하는 세포, 및 항원에 특이적인 면역조절 세포의 제조 및/또는 생성에서의 이들의 용도에 관한 것이다.

CULTURE METHOD, GROUP OF MATURE ADIPOCYTES, AND DRUG SCREENING METHOD

Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases

MANUFACTURING METHOD OF MULTI ORGAN MICROFLUIDIC CHIP STRUCTURE AND MULTI ORGAN MICROFLUIDIC CHIP STRUCTURE

METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF AN ALLOGENIC CELL AND THERAPEUTIC USES

COMPOSITION FOR TRANSPLANTATION COMPRISING ADIPOSE STEM CELLS OR ADIPOCYTES

The present invention relates to a composition for transplantation in a physiologically compatible buffer solution comprising, (a) a transplant-cell selected among an adipose stem cell, an adipocyte, adipose tissues (fat tissue) and a mixture thereof; and (b) a semi-solid substance derived from a living body or a biodegradable substance selected among a hyaluronic acid, collagen, elastin, thrombin, chondroitin sulfate, albumin and a mixture thereof.

COMPRESSED CELL OR COMPRESSED TISSUE AS CELL MODEL OF PATHOLOGICAL CONDITION AND MANUFACTURING METHOD THEREFOR

The purpose of the present invention is to provide cultured cells necessary for elucidating the pathology of obesity, metabolic syndrome, diabetes, dyslipidemia, hypertension or atherosclerosis and screening diagnostic drugs/therapeutic drugs. It was discovered that cells (tissue) similar to obese fat cells of a desired pathology could be manufactured using a cell compression culturing method of compressing normal fat cells or normal fat tissue or obese fat cells or obese fat tissue and culturing. As a result, use of said compressed fat cells (tissue) makes possible a novel method with which compounds capable of treating metabolic syndrome, etc. can be screened in a system that is more similar to a living body.

HYBRID SOFT TISSUE IMPLANTS FROM PROGENITOR CELLS AND BIOMATERIALS

Provided are hybrid soft tissue constructs comprising a core material, a biomaterial matrix and mammalian cells. Also provided are methods of augmenting or reconstructing a soft tissue of a mammal. Additionally, methods of forming a hybrid soft tissue construct are provided. The use of the above constructs for augmenting or reconstructing a soft tissue of a mammal are further provided. Additionally provided is the use of the above constructs for the manufacture of a medicament for augmenting or reconstructing a soft tissue of a mammal.

METHOD OF INDUCING DIFFERENTIATION FROM VISCERAL PREADIPOCYTE TO VISCERAL ADIPOCYTE

The invention provides a method of inducing differentiation of a visceral preadipocyte and a method of culturing a visceral adipocyte comprising culturing the cell in a medium containing serum free of heparin-adsorbable components. The invention also provides for the removal of heparin-adsorbable components by, for example, applying serum to a heparin affinity column thereby adsorbing the heparin-adsorbable component to heparin. A visceral adipocyte cultured by the method of the present invention is useful in a study of differentiation, growth and metabolism of an adipocyte, elucidation of the mechanism of development and progress of diseases such as diabetes, hyperlipemia, hypertension and arteriosclerosis, and development of a drug for preventing and treating such a disease.

AUGMENTATION AND REPAIR OF DERMAL, SUBCUTANEOUS, AND VOCAL CORD TISSUE DEFECTS

The application concerns a method for corrective surgery of defects being amenable to rectification by the augmentation of tissue subjacent to the defect. The method involves retrieving viable cells from a subject, a neonate or human fetus. The cells are then cultured in vitro and placed into a tissue of the subject, the tissue being located in a position subjacent to the defect to be rectified. Alternatively, the cells may be cultured in a collagen matrix or suspended in a collagen matrix prior to being placed in a position subjacent to the defect to be rectified. In a further embodiment, the cells are cultured and the in vitro produced extracellular matrix is collected and placed in a position subjacent to the defect to be rectified. A method for the correction of vocal cord defects is also disclosed.

Apparatuses, systems, and methods for culturing cells

Apparatuses, systems, and methods are provided for culturing a buoyant target tissue. Embodiments include a first surface configured to culture a first layer of supporting cells, and a second surface configured to culture a second layer of supporting cells. The first layer of supporting cells may be formed on a portion of the first surface and the second layer of supporting cells may be formed on a portion of the second surface. The buoyant target tissue may be added to the first layer of supporting cells. The second layer of supporting cells may be placed on the first layer of supporting cells such that the buoyant target tissue is sandwiched between the first layer of supporting cells and second layer of supporting cells.

ADIPOSE-DERIVED STEM CELL PRODUCT

The present invention discloses adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF), their compositions and kits containing the ADSC's and their enriched fractions, and enzyme blends useful for their isolation, as well as methods of their isolation and use.

PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD

Human progenitor cells are extracted from perivascular tissue of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours osteogenic progenitor cells and MHC−/− progenitor cells, and is useful to grow and repair human tissues including bone. 1. An isolated Wharton's jelly extract , wherein the extract comprises human progenitor cells and is obtained by enzymatic digestion of the perivascular tissue proximal to the vasculature of human umbilical cord.2. The Wharton's jelly extract of claim 1 , wherein the extract is essentially free from cells of umbilical cord blood.3. The Wharton's jelly extract of claim 2 , wherein the extract is obtained by subjecting umbilical cord vasculature bearing proximal Wharton's jelly to enzymatic digestion in a suitable cell extraction medium.4. The Wharton's jelly extract of claim 3 , wherein the step of enzymatic digestion results in the release of cells from the collagen matrix of the Wharton's jelly.5. The Wharton's jelly extract of claim 4 , in which the extraction is performed at 37° C. in phosphate buffered saline and 0.5-10.0 mg/mL collagenase for a period of 1 to 24 hours.6. A method for obtaining one or more human progenitor cells claim 1 , comprising the step of isolating said one or more cells from the Wharton's extract of .7. The method of claim 1 , wherein said method comprises producing a cell population comprising said human progenitor cells comprising the step of culturing at least one said human progenitor cell obtained by the method of .8. A cell population comprising human progenitor cells claim 7 , whenever obtained by the method of .9. An isolated cell population useful as a source of human progenitor cells claim 7 , wherein the cell population is extractable from perivascular tissue of human umbilical cord claim 7 , and has the characteristics of (1) rapid proliferation claim 7 , (2) the presence of osteoprogenitor cells claim 7 , and (3) the presence of immuno-incompetent cells.10. ...

HAIR GROWTH-PROMOTING COMPOSITION AND METHOD FOR PROMOTING HAIR GROWTH

Provided is a hair growth-promoting composition comprising: 100 parts by weight of a stem cell culture solution obtained from a culture medium of mesenchymal stem cells which have been subcultured two or more times; 0.001 to 0.1 parts by weight of zinc; 5 to 50 parts by weight of a panthenol based compound; and 0.0001 to 0.1 parts by weight of a water-soluble vitamin, wherein it is sprayed or applied on the scalp to promote hair growth. Said hair growth-promoting composition may have an excellent effect and improve economical efficiency in treating alopecia due to a simple delivery method of the composition.

Anti-obesity potential of Calebin A

The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-), Interleukin-6 (IL-6) and Interleukin-1 (IL-1).

METHODS OF OBTAINING CELL POPULATIONS FROM ADIPOSE TISSUE

СПОСОБ ЭКСПАНСИИ КЛЕТОК, СПОСОБ ПОЛУЧЕНИЯ КОНДИЦИОННОЙ СРЕДЫ, ПОПУЛЯЦИЯ АДГЕЗИВНЫХ МЕЗЕНХИМАЛЬНЫХ СТРОМАЛЬНЫХ КЛЕТОК ПЛАЦЕНТЫ ИЛИ ЖИРОВОЙ ТКАНИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АДГЕЗИВНЫХ МЕЗЕНХИМАЛЬНЫХ СТРОМАЛЬНЫХ КЛЕТОК ПЛАЦЕНТЫ ИЛИ ЖИРОВОЙ ТКАНИ В ТРАНСПЛАНТАЦИИ

Изобретение относится к области биотехнологии, конкретно к получению мезенхимальных стромальных клеток плаценты или жировой ткани, и может быть использовано в медицине. Способ экспансии клеток включает культивирование адгезивных мезенхимальных стромальных клеток из плаценты или жировой ткани в трехмерных условиях культивирования, которые содействуют экспансии клеток. Изобретение позволяет получить адгезивные мезенхимальные стромальные клетки плаценты или жировой ткани, которые возможно использовать для поддержания гематопоэтических стволовых клеток, для иммуносупрессии, для получения кондиционных сред и в транспланталогии. 6 н. и 16 з.п. ф-лы, 22 ил., 3 табл.

СПОСОБЫ ЭКСПАНСИИ КЛЕТОК И ПРИМЕНЕНИЕ КЛЕТОК И КОНДИЦИОННЫХ СРЕД, ПОЛУЧЕННЫХ ТАКИМ ОБРАЗОМ, ДЛЯ ЛЕЧЕНИЯ

... 1. Способ экспансии клеток, причем способ включает культивирование адгезивных клеток из плаценты или жировой ткани в трехмерных условиях культивирования, которые содействуют экспансии клеток. ! 2. Способ по п.1, в котором трехмерная культура включает 3D-биореактор. ! 3. Способ п.1, в котором культивирование осуществляют, по меньшей мере, в течение 3 дней. ! 4. Способ по п.1, в котором указанное культивирование осуществляют до достижения, по меньшей мере, 60% конфлюэнтности. ! 5. Способ по п.1, где указанные адгезивные клетки содержат чип экспрессии позитивных маркеров, выбранный из группы, состоящей из CD73, CD90, CD29 и CD105. ! 6. Способ по п.1, где указанные адгезивные клетки содержат чип экспрессии негативных маркеров, выбранный из группы, состоящей из CD45, CD80, HLA-DR, CD11b, CD14, CD19, CD34 и CD79. ! 7. Способ по п.1, где указанные адгезивные клетки или среда характеризуются более высокой иммуносуппрессирующей активностью, чем активность адгезивных клеток плаценты или жировой ткани ...

Системы и способы для управления изделиями медицинского назначения

СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К БУРЫМ ЖИРОПОДОБНЫМ КЛЕТКАМ

... 1. Выделенные, дифференцированные вне организма бурые жироподобные клетки артериального происхождения.2. Бурые жироподобные клетки по п. 1, дополнительно характеризуемые экспрессией по меньшей мере одного маркера адипоцита, выбранного из группы, состоящей из связывающего белка 4 (аР2) жирных кислот, рецептора α (PPARα), активированного пролифератором пероксисомы, рецептора γ (PPARγ), активированного пролифератором пероксисомы, адипонектина (ADN), разобщающего белка 1 (UCP-1), PR-домена, содержащего белок 16, (PRDM16), PPAR-коактиватора-1α (PGC-1α), CCAAT/гена-усилителя связывающего белка β (C/EBPβ), DFFA-подобного А эффектора (CIDE-А) и удлинения жирных кислот с очень длинной цепью, таких как белок 3 (ELOVL3).3. Бурые жироподобные клетки по п. 2, в которых маркер адипоцита может представлять собой бурый маркер адипоцита, выбранный из группы, состоящей из расцепляющего белка1 (UCP-1), PR-домена, содержащего белок 16, (PRDM16), PPAR-коактиватора-1α (PGC-1α), CCAAT/гена-усилителя связывающего ...

VON ADIPÖSEM GEWEBE STAMMENDE STROMALE STAMMZELLEN ZUR VERWENDUNG BEI DER BEHANDLUNG BEHANDLUNGSRESISTENTER KOMPLEXER PERIANALFISTELN BEI MORBUS CROHN

Vermehrte, allogene, von adipösem Gewebe stammende stromale Stammzellen zur Verwendung in einem Verfahren zur Behandlung einer behandlungsresistenten komplexen Perianalfistel, die mehrere Gänge umfasst, in einem Patienten mit Morbus Crohn, wobei(i) dem Patienten in einem einzelnen Vorgang eine Dosis von etwa 120 Millionen Zellen verabreicht wird, wobei jeder Gang der Fistel zumindest einen Teil dieser Dosis erhält und wobei ungefähr die Hälfte der Dosis in das Gewebe injiziert wird, das die innere Öffnung oder inneren Öffnungen umgibt, und die andere Hälfte der Dosis entlang der Gänge der Fistel in die Fistelwände injiziert wird und(ii) die Therapie eine klinische Rückbildung innerhalb von 8 Wochen induziert.

DEDIFFERENZIERTE, PROGRAMMABLE MAIN CELLS MONOZYTÄREN OF ORIGIN, AS WELL AS THEIR PRODUCTION AND USE

USE OF DIFFERENTIATED FIBROBLASTS OR A PRIMARY FIBROBLAST CULTURE TO TRANSDIFFERENZIERUNG IN FAT, KNOCHENUND CARTILAGE CELLS

USE FROM FATTY TISSUE CELLS TO THE INTRODUCTION OF THE EDUCATION OF A FUNCTIONAL CONTAINER NET

PRIMARY CULTIVATED ADIPOZYTEN TO THE GENE THERAPY

USE OF FATTY TISSUE-DERIVED STROMALEN CELLS FOR DIFFERENTIATION IN CHONDROZYTEN AND YOUR USE TO THE REPAIR OF CARTILAGE FABRIC

ADIPOGENI DIFFERENTIATION OF HUMAN MESENCHYMALEN MAIN CELLS

SEBOZYTEN, SEBOZYTEN ZELLINIE ONE AND THEIR USES

Methods and compositions for preventing obesity and obesity related disorders

Augmentation and repair of dermal, subcutaneous, and vocal cord tissue defects

Method and apparatus for increasing adipose vascular fraction

Systems and methods for medical device control

Systems, devices, and methods of the present disclosure assist with management of tubes and hoses during surgical procedures. The systems, devices, and methods provide for the proper opening and closing of tubes to facilitate performance of steps in a surgical procedure. Systems, devices, and methods of the present disclosure control fluid delivery to and from a medical device, including devices for tissue processing and cleaning.

Compositions and methods for implantation of processed adipose tissue and processed adipose tissue products

The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue.

Methods for increasing thermogenic adipocytes

In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.

Stem cells and secretions for treatment of inflammatory conditions

The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.

SYSTEMS AND METHODS FOR ISOLATING MICROVESSELS FROM ADIPOSE TISSUE

Methods and systems to isolate microvessels using an enriched or purified enzyme to dissociate tissue are described. The systems and methods include a second digestion to digest a top layer, from a first digestion and first centrifuge operation, with the enriched or purified enzyme to generate a second fat-enzyme solution, a second centrifuge operation, and isolation of the microvessels from pellets generated by the first and second centrifuge operations. The systems and methods may include washing the second fat-enzyme solution with an enzyme inhibitor in a post-digestion wash.

METHOD FOR OBTAINING DIFFERENTIATED CELLS FROM MUSCLE DERIVED PROGENITOR CELLS

The present invention relates to a method for preparing differentiated mammalian cells comprising collecting muscle microbiopsy, placing the sample in a cell culture medium, collecting and growing the cells and differentiating them in suitable differentiation medium.

NON-ENZYMATIC METHOD AND MILLING DEVICE

Non-enzymatic method and milling device for preparing therapeutic cells from adipose tissue comprising: continuously feeding the adipose tissue to the milling device (2); mechanically separating the cells or cell aggregates from adipose tissue moving through the milling device (2) by means of a multiplicity of blades (19) of a rotor (10), wherein the blades (19) are arranged in a spaced arrangement with respect to the overall direction of flow and the blades (19) are moving about an axis of rotation (18), wherein the axis of rotation (18) is provided essentially parallel to said overall direction of flow; continuously withdrawing the processed tissue comprising the separated cells from the milling device (2).

METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONEDMEDIA PRODUCED THEREBY FOR THERAPY

A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion.

THREE DIMENSIONAL CELL CULTURE

A method for culturing preadipocytes isolated ex vivo is described, the method including introducing preadipocytes into a three dimensional support matrix, and allowing the cells to differentiate in vitro into adipocytes within the support matrix. The matrix may be a collagen matrix. The method may be used for investigating the development of stem cells, or for investigating the response of adipocytes to stimuli. The method provides a system whereby adipocytes with biological properties resembling those in vivo can be grown in vitro.

COMPOSITIONS AND METHODS FOR IMPLANTATION OF ADIPOSE TISSUE AND ADIPOSE TISSUE PRODUCTS

The invention provides compositions and methods for the preparation of biocompatible biomaterials from adipose tissue. Biocompatible biomaterials are cellular or acellular biomaterials. The invention further provides methods of use of the biocompatible biomaterials.

BROWN ADIPOCYTE PROGENITORS IN HUMAN SKELETAL MUSCLE

Brown adipose tissue ("BAT") progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 ("UCP 1"), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and/or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of, or the making of medicaments for the treatment of, metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation ...

ADHERENT CELLS FROM PLACENTA TISSUE AND USE THEREOF IN THERAPY

A method of culturing adherent cells from a placenta or adipose tissue is disclosed. The method comprising culturing the adherent cells from the placenta or adipose tissue under 3 dimensional (3D) culturing conditions which allow cell expansion, the conditions comprising perfusion.

CULTURE ADDITIVES TO BOOST STEM CELL PROLIFERATION AND DIFFERENTIATION RESPONSE

The invention relates to methods of culturing and/or proliferating stem cells such as progenitor cells, multipotent and induced pluripotent stem (IPS) cells. More particularly, the invention relates to the use of macromolecular crowding created using carbohydrate-based macromolecule to promote the growth of the stem cells in an ex vivo culture, while preserving their multipotentiality.

CELL CULTURE SCREEN FOR AGENTS THAT CONTROL ADIPOGENESIS AND MYOFIBROBLAST DIFFERENTIATION

Methods are provided for the rapid and robust screening test agents for adipogenic activity. Agents testing positive in the assays are good candidate agents for wrinkle reduction, normalizing skin appearance after reconstructive or cosmetic surgery, e.g., grafted tissue on burn victims, normalizing skin appearance during and after wound healing, and the like. In certain embodiments the methods involve providing mammalian test cells with adipogenic potential wherein said cells are primed for, but withheld from differentiation into adipocytes; contacting the cells with the test agent(s); and screening said test cells for an adipocyte phenotype wherein the presence of a feature characteristic of an adipocyte is an indicator that said test agent is adipogenic.

MODIFICATION OF THE IMMUNOMODULATORY EFFECTS OF CELLS

La présente invention concerne une cellule isolée possédant un potentiel immunomodulateur, dans laquelle l'expression et/ou l'activité de la périostine est modulée, ou le surnageant de culture de ladite cellule, pour son utilisation comme médicament immunosuppresseur ou immunostimulateur. La présente invention concerne également la périostine pour son utilisation comme médicament immunostimulateur ou un inhibiteur de la périostine pour son utilisation comme médicament immunosuppresseur.

METHOD FOR ISOLATION AND PURIFICATION OF EPITHELIAL STEM CELLS FROM SKIN

The current invention concerns a method for obtaining a cellular composition comprising epithelial stem cells (EpSCs) from mammalian skin, whereby said composition comprises at least 90% of viable EpSCs, comprising the steps of: - obtaining a mammalian skin sample; - obtaining a cell suspension from said skin sample by performing at least one enzymatic dissociation step; and - culturing said cell suspension under low-attachment conditions. Preferably cellular composition comprises epithelial stem cells derived from the epidermal layer. In a second aspect, the current invention provides for a cellular composition obtained by the method according to the invention.

METHODS AND COMPOSITIONS RELATED TO BROWN ADIPOSE-LIKE CELLS

Methods and therapeutics are provided for treating diseases, including metabolic diseases and other weight-related disorders. Generally, methods for making brown adipose-like including culturing a population of artery-derived cells in adipogenic induction medium for a period of time and under conditions sufficient to increase expression of at least one adipocyte marker at a higher level as compared to untreated artery-derived cells are disclosed. Isolated artery-derived, ex vivo differentiated brown adipose-like cells are also provided, including pharmaceutical compositions and cell delivery systems thereof. In another embodiment, a method of treating a subject is disclosed that includes obtaining a population of artery-derived brown adipose-like cells and administering the brown adipose-like cells into a target region in the subject.

ADIPOGENIC DIFFERENTIATION OF HUMAN MESENCHYMAL STEM CELLS

A composition which comprises human mesenchymal stem cells which have the potential to differentiate into cells of more than one connective tissue type and a composition which induces cells from the mesenchymal stem cell population to differentiate into the adipogenic lineage, and a process for inducing such differentiation. The composition for inducing such differentiation comprises a glucocorticoid and a compound which stimulates cAMP production or inhibits cAMP degradation (such as a phosphodiesterase inhibitor). The process can further include isolating the adipocytes from remaining hMSCs.

REPAIR OF AUTOLOGOUS TISSUE DEFECTS

This invention is a methodology for the long-term augmentation, and/or repair of dermal, subcutaneous, or vocal cord tissue by the injection, or direct surgical placement of autologous cultured fibroblasts derived from connective tissue, or dermis, or fascia lamina propria tissue fibroblasts derived from the lamina propria or adipocytes. The fibroblast cultures utilized for the augmentation, and/or repair of skin defects are derived from either connective tissue, dermal, and/or fascial fibroblasts. In addition a methodology of rendering the cultured cells substantially free of potentially immunogenic serum derived proteins by late stage passage of the cultured fibroblasts lamina propria tissue, or adipocytes in serum free medium in the patient's own serum.

Soft gel systems in modulating stem cell development

This invention provides gels and matrices having a rigidity in the range of 150-750 Pa, methods of manufacturing same, and method of preserving a mesenchymal stem cell population or studying mesenchymal stem cells, comprising same.

CELL PREPARATION METHOD, CELL CULTIVATION DEVICE, AND KIT

PROCESS OF CULTURE Of ADIPOCYTES

La présente invention concerne un procédé de culture d'adipocytes, dans lequel une population homogène d'adipocytes matures isolés de tissu adipeux est cultivée sur un support de culture tridimensionnel.

METHOD FOR IN VITRO PRODUCTION OF ADIPOCYTE PROGENITOR AND ADIPOCYTES

La présente invention concerne un procédé de production in vitro de progéniteurs adipocytaires et d'adipocytes à partir de cellules souches pluripotentes, en particulier de cellules souches pluripotentes induites, ainsi que l'utilisation à des fins thérapeutiques ou de criblage des progéniteurs adipocytaires et adipocytes ainsi obtenus.

dopaminérgicos neurÈnios derivatives of limbus corneal, methods of isolation and uses of the same ones

CELL DELIVERY MATRICES

Cell delivery matrices and methods for facilitating local delivery of adipose derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patient's own body. The cell delivery matrix may be biocompatible and semi-permeable. The cell delivery matrix used in the methods of the invention may be comprised of any degradable, bioabsorbable or non-degradable, biocompatible polymer. Regenerative therapies comprising implanting in the subject cell delivery matrices localizing adipose derived endothelial cells are described. The cell delivery matrices maintain the adipose derived endothelial cells at the target for a therapeutically effective amount of time. The adipose derived endothelial cells can be allogenic or syngenic to the subject. The endothelial cells may be delivered alone or in combination with other therapeutic agents.

BROWN ADIPOCYTE DIFFERENTIATION-INDUCING AGENT

The present invention addresses the problem of providing a means which is effective for the induction of the differentiation of a brown adipocyte and therefore enables a brown adipocyte to be used for and applied to, for example, the prevention/treatment of obesity or metabolic syndrome. Provided is a brown adipocyte differentiation-inducing agent containing, as an active ingredient, (1) CREG1 protein or (2) an expression vector carrying CREG1 gene.

METHOD FOR DENTAL PULP CRYOPRESERVATION

The present invention relates to a method for cryopreserving the pulp of a non- exfoliated deciduous tooth, comprising a step of making with a laser a hole into the tooth removed from its physiological seat on the tooth neck. After making the hole, the tooth is contacted with a cryopreserving agent and then cryofrozen. An object of the invention further consists in mesenchymal stem cells isolated from the pulp of a cryopreserved tooth according to the method of the invention.

METHODS OF OBTAINING CELL POPULATIONS FROM ADIPOSE TISSUE

Provided herein are methods of efficiently obtaining large numbers of viable, freshly isolated cells from small amounts of adipose tissue, as well as methods of enriching or selecting for target cell populations found therein. In certain embodiments, the method of obtaining a population of cells from adipose tissue comprises incubating the adipose tissue in a solution comprising an enzyme at a concentration which is at least 200 U/ml solution and not more than about 319 U/ml solution. In some embodiments, the method is devoid of any steps which expand the population of cells obtained. In certain aspects, the method further comprises positive or negative selection steps for obtaining an enriched population of target cells from adipose tissue. Related methods of preparing a pharmaceutical composition comprising cells for administration to a patient and methods of treating a disease or medical condition in a patient are further provided herein.

METHOD FOR CULTIVATING LIVING CELLS, ESPECIALLY MATURE FAT CELLS, WHICH ARE PREPARED FROM TISSUE AND FLOAT IN LIQUIDS

L'invention concerne un procédé de culture de cellules vivantes préparées à partir de tissus, qui surnagent dans un liquide, en particulier d'adipocytes matures. Selon ledit procédé, on applique d'abord les cellules avec, comme auxiliaire de répartition, un milieu liquide d'adhésion, sur le fond de culture cellulaire d'une boîte de culture cellulaire, fond auquel lesdites cellules adhèrent mécaniquement avec une évaporation croissante du milieu d'adhésion, puis on recouvre les cellules avec le milieu d'adhésion et on les stocke pendant au moins douze heures dans des conditions standards pour la culture cellulaire, temps pendant lequel au moins quelques cellules adhèrent biologiquement au fond de culture cellulaire. Ainsi, on obtient, au moyen de boîtes de culture cellulaire, un procédé techniquement simple et économique de culture de cellules sur des fonds de culture cellulaire, avec un haut rendement. Grâce à cette culture in vivo de cellules indépendantes, on constitue la base, ...

COMPOSITIONS AND METHODS FOR MODULATING DESNUTRIN-MEDIATED ADIPOCYTE LIPOLYSIS

The present disclosure provides methods of converting white adipose tissue to brown adipose tissue in an individual, generally involving modulating desnutrin-mediated lipolysis in adipocytes in the individual. The present disclosure further provides methods for treating obesity. The present disclosure further provides methods of identifying an agent that increases the level and/or activity of desnutrin in an adipocyte.

Adipose-derived stem cells and lattices

The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

Method of Preconditioning of Cell Suspensions

An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway.

Brown Fat Cell Compositions and Methods

Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes. 1. A method of generating a stem cell , comprising:obtaining brown fat tissue;isolating a stem cell from the brown fat tissue; andculturing the stem cell in a medium not comprising an animal product, thereby generating a stem cell.2. The method of claim 1 , wherein the brown fat tissue is from a sample obtained from a subject.3. The method of claim 1 , wherein the stem cell is positive for one or more of the following cell surface markers: CD63 claim 1 , CD90 claim 1 , HLA ABC claim 1 , CD105 claim 1 , CD73 claim 1 , CD166 claim 1 , CD 9 claim 1 , CD44.4. The method of claim 1 , wherein the stem cell is negative for one or more of the following cell surface markers: CD34 claim 1 , CD19 claim 1 , CD86 claim 1 , HLA DR claim 1 , Lin claim 1 , CD106 claim 1 , CD80 claim 1 , CD 117.5. A method of treating a metabolic disorder in a subject claim 1 , comprising:removing a stem cell from a donor;differentiating the stem cell into a brown adipocyte in a medium not comprising an animal product; andadministering the brown adipocyte to a fat deposit within the subject, thereby treating the metabolic disorder in the subject.6. The method of claim 5 , wherein the metabolic disorder is selected from the group consisting of obesity claim 5 , central obesity claim 5 , diabetes claim 5 , hypertension claim 5 , cardiac deficiency claim 5 , ischemic cardiac disease claim 5 , high blood pressure claim 5 , triglyceride dyslipidemia claim 5 , HDL dyslipidemia claim 5 , cholesterol dyslipidemia claim 5 , elevated fasting plasma glucose claim 5 , leptin dysregulation claim ...

Method for obtaining pancreatic endocrine cells from adipose tissue-origin cells

A method of obtaining pancreatic endocrine cells from cells originating in an adipose tissue characterized by comprising culturing the adipose tissue-origin cells; the pancreatic endocrine cells that can be obtained thereby; a method of treating or preventing a disease caused by the hypofunction in pancreatic endocrine cells wherein the above-described pancreatic endocrine cells are used; a method of screening a substance capable of promoting or inhibiting the differentiation into pancreatic endocrine cells characterized by comprising adding a candidate substance to a medium in the course of culturing adipose tissue-origin cells to obtain the pancreatic endocrine cells; and so on.

Methods of Screening Embryonic Progenitor Cell Lines

Aspects of the present invention include methods and compositions related to the production and use of numerous clonal lineages of embryonic progenitor cell lines derived from differentiating cultures of primordial stem cells with diverse molecular markers and having been cultured for >21 doublings of clonal expansion. The robustness of these clonally-purified lines, their ability to expand for >40 passages while maintaining their pattern of gene expression, lack of tumorigenicity, and their embryonic pattern of gene expression offers novel compositions and methods for modeling numerous differentiation pathways for the first time in vitro, and for the manufacture of purified product not existing in such a purified state in nature or using other manufacturing modalities. Representative progenitor cell lines described herein are capable of development into cutaneous adipocytes, blood-brain barrier cells, neuronal cells, or smooth muscle cells each with therapeutic potential. 1. An isolated clonal progenitor cell line expressing EYA4 , wherein the clonal progenitor cell line is an embryonic cutaneous progenitor cell.2. The isolated clonal progenitor cell line of claim 1 , wherein the cell line also expresses ADH1A claim 1 , ADH1B claim 1 , FABP4 claim 1 , CD36 claim 1 , PPARG claim 1 , ANGPT2 claim 1 , EBF2 AND DBC1.3. The isolated clonal progenitor cell line of claim 1 , wherein the cell line is encapsulated in a biomaterial.4. The isolated clonal progenitor cell line of claim 3 , wherein the biomaterial comprises a hydrogel.5. The isolated clonal progenitor cell line of claim 3 , wherein the biomaterial comprises hyaluronic acid.6. The isolated clonal progenitor cell line of claim 3 , wherein the biomaterial is chosen from calcium alginate claim 3 , agarose claim 3 , polylactic acid/poly-glycolic acid derivatives claim 3 , and fibrin.76. A kit comprising the cell line of -.8. A method of differentiating a clonal progenitor cell line into cutaneous adipocytes ...

COMBINATIONS OF PROTEINS TO ENHANCE VIABILITY OF STEM CELLS AND THEIR PROGENITORS BEFORE TRANSPLANTATION

Embodiments of the present invention include the use of placental alkaline phosphatase alone or in combination with human transferrin and, optionally, human α-antitrypsin to enhance the proliferation and survival of transplanted stem cells and stem cell-derived progenitor cells. 1. A method for stimulating proliferation and promoting survival of mesenchymal stem cells , or hematopoietic stem cells , or their progenitor cells before transplantation , the method comprising the steps of (i) contacting the mesenchymal stem cells , or hematopoietic stem cells , or their progenitor cells with a first composition comprising 1-50μ per ml of an active PALP in a suitable cell culture medium containing 0-10% serum , and (ii) harvesting said cells for transplantation in a suitable medium supplemented with a second composition comprising an active PALP.2. The method of claim 1 , wherein the first composition claim 1 , or the second composition claim 1 , or both compositions further comprise active transferrin or active α1-antitrypsin claim 1 , or both active transferrin and active α1-antitrypsin.3. The method of claim 1 , wherein the active PALP is a recombinant protein.4. The method of claim 1 , wherein the active PALP is a placental alkaline phosphatase protein derivative.5. The method of claim 2 , wherein active transferrin or active α1-antitrypsin are recombinant proteins.6. The method of claim 1 , wherein the first and second compositions each comprise 1-50 μg/ml of an active PALP.7. The method of claim 2 , wherein the first composition claim 2 , the second composition claim 2 , or both compositions comprise 1-50 μg/ml of active transferrin claim 2 , 50-500 μg/ml of active α1-antitrypsin claim 2 , or both 1-50 μg/ml of active transferrin and 50-500 μg/ml of active α1-antitrypsin.8. The method of claim 1 , wherein the active PALP is pre-incubated at 65-75° C. for 30 minutes before being added to said cells in steps (i) or (ii).9. The method of claim 2 , wherein the active α1 ...

SYSTEM AND APPARATUS FOR CELL TREATMENT

The present invention relates to systems and apparatuses for improving quality and viability of biological material, such as harvested adipose cells, stem cells, or other cells or biological components, by treatment of the biological material with membrane-repairing/stabilizing agents or the like and/or mechanical removal of components, such as impurities and/or excess treatment agents. The present invention further relates to systems and apparatuses for transplanting tissue, such as adipose tissue. 1. An apparatus comprisinga chamber having at least one outlet; anda pressure generating device configured and arranged for generating a positive pressure within the chamber that is at or below a predetermined threshold, the positive pressure being sufficient to cause a biological material, if present in the chamber, to discharge through the outlet, wherein the predetermined threshold is a pressure above which the biological material has relatively low viability as a tissue graft following discharge from the outlet into a graft site in a subject.2. The apparatus of claim 1 , wherein the positive pressure is maintained such that the velocity of the biological material discharging from the outlet is up to about 265 cm/sec.3. The apparatus of claim 1 , wherein the positive pressure is maintained such that the flow rate of the biological material discharging from the outlet is below 3 ml/sec.4. The apparatus of claim 1 , wherein the predetermined threshold is 4 atm.5. The apparatus of claim 1 ,wherein the outlet is positioned at a distal end of the chamber,wherein the chamber comprises an opening at a proximal end, andwherein the pressure generating device is a plunger arrangement configured and arranged to pass through the opening and to be movably disposed in the chamber, such that displacement of the plunger arrangement within the chamber toward the distal end generates the positive pressure.6. The apparatus of claim 5 , wherein the plunger arrangement comprises a force- ...

APPARATUS AND METHODS RELATING TO COLLECTING AND PROCESSING HUMAN BIOLOGICAL MATERIAL CONTAINING ADIPOSE

A portable apparatus for collection and processing of human biological material containing adipose, such as extracted during a lipoplasty procedure, is useful for multi-step processing to prepare a concentrated product (e.g., stromal vascular fraction) or a fat graft composition. The apparatus has a container with a containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a tapered portion to a collection volume for collecting concentrate product. Inlet and suction ports provide access to the tissue retention volume and filtrate volume, respectively, and an extraction port provides versatile access for removal of target processed concentrate material or fat graft material, which access may be via a lumen through a rotatable mixer shaft. Access ports may be configured for access only from above the container. The apparatus is incorporatable into a variety of assemblies, systems, kits, methods and uses. 1. An apparatus useful for collection of human biological material and post-collection processing of collected material , the apparatus being orientable in a collection orientation , as oriented in the collection orientation the apparatus comprising:a filter; a tissue retention volume and a filtrate volume separated by the filter;', 'a collection volume within the filtrate volume, the collection volume having a bottom elevation corresponding to a bottom elevation of the filtrate volume and a top elevation that is lower than the bottom elevation of the tissue retention;', 'a tapered portion that tapers in a downward direction with at least a portion of the tapered portion being located above the collection volume;, 'a container having an internal containment volume, the internal containment volume comprisingan inlet port in fluid communication with the tissue retention volume and configured for introducing human biological material comprising adipose directly into the tissue retention volume;a suction port in fluid ...

Method for Culturing Adipocytes

The present invention relates to a method for culturing adipocytes, in which a homogeneous population of mature adipocytes isolated from adipose tissue is cultured on a three-dimensional culture substrate. 1. A method of culturing adipocytes , comprising culturing a homogeneous population of mature adipocytes isolated from adipose tissue on a three-dimensional culture substrate.2. The method for culturing adipocytes as claimed in claim 1 , wherein the three-dimensional culture substrate is a hydrogel.3. The method for culturing adipocytes as claimed in or claim 1 , wherein the three-dimensional culture substrate is a hydrogel formed from the noncovalent association of peptides comprising from 10 to 30 residues.4. The method for culturing adipocytes as claimed in claim 3 , wherein the peptides comprise the sequence R-A-D-A-R-A-D-A-R-A-D-A-R-A-D-A (SEQ ID NO: 11).5. The method for culturing adipocytes as claimed in one of claim 1 , wherein the adipose tissue was taken from one or more human individuals.6. An adipocyte culture claim 1 , comprising a monoculture of mature adipocytes isolated from adipose tissue claim 1 , in contact with a three-dimensional culture substrate.7. The adipocyte culture as claimed in claim 6 , wherein the adipose tissue was taken from one or more human individuals.8. A method of screening compounds which modulate adipocyte metabolism comprising contacting the compound with an adipocyte culture as defined in and measuring adipocyte metabolism claim 6 , wherein a change in adipocyte metabolism indicates a compound which modulates adipocyte metabolism.9. The method as claimed in claim 8 , further comprising screening compounds which activate lipolysis.10. The method as claimed in claim 8 , further comprising screening compounds which activate the PPARγ2 transcription factor. The invention relates to a method for culturing adipocytes, to an adipocyte culture, and to the use thereof for screening compounds which modulate adipocyte metabolism.The ...

FAT CELLS AND METHODS OF USING THEREOF

Beige cells that contain a reporter gene are disclosed herein. Such cells can be used to identify therapeutic agents for treatment of obesity and its associated disorders, such as diabetes. 1. A beige cell comprising a reporter gene wherein the reporter gene is under the control of a gene in the PRDM16 pathway.2. The beige cell of claim 1 , wherein said gene is PRDM16.3. The beige cell of claim 1 , wherein the cell is claim 1 , a human cell or a mouse cell.4. The beige cell of claim 1 , wherein the cell is a primary cell claim 1 , a non-primary cell claim 1 , an immortalized cell claim 1 , or a clonal cell.5. The beige cell of claim 1 , wherein the reporter gene encodes a protein which luminesces or fluoresces claim 1 , which is colored or produces a colored substrate or an enzymatic activity.6. The beige cell of claim 1 , wherein the reporter gene encodes a protein selected from the group consisting of luciferase claim 1 , green fluorescent protein (GFP) claim 1 , red fluorescent protein (RFP) claim 1 , yellow fluorescent protein (YFP) claim 1 , chloramphenicol acetyltransferase (CAT) claim 1 , alkaline phosphatase (AP) claim 1 , β-galactosidase (β-gal) claim 1 , β-lactamase (Bla) claim 1 , horseradish peroxidase (HRP) claim 1 , and a variant thereof.7. The beige cell of claim 1 , wherein the genetic locus is selected from PRDM16 claim 1 , PGC-1α claim 1 , and PGC-1β.8. The beige cell of claim 1 , wherein the cell is derived from the stromal-vascular fraction (SVF) of a subject.9. A method of evaluating a compound claim 1 , the method comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'providing a beige cell of ;'}contacting a compound the cell; anddetermining the activity of the reporter gene expression product; thereby evaluating a compound.10. The method of claim 9 , further comprising selecting a compound that increases the activity of the reporter gene expression product by at least about 2 claim 9 , 5 claim 9 , 10 claim 9 , 20 claim 9 , 40 claim 9 , ...

METHODS AND COMPOSITION RELATED TO BROWN ADIPOSE-LIKE CELLS

Methods and therapeutics are provided for treating diseases, including metabolic diseases and other weight-related disorders. Generally, methods for making brown adipose-like including culturing a population of artery-derived cells in adipogenic induction medium for a period of time and under conditions sufficient to increase expression of at least one adipocyte marker at a higher level as compared to untreated artery-derived cells are disclosed. Isolated artery-derived, ex vivo differentiated brown adipose-like cells are also provided, including pharmaceutical compositions and cell delivery systems thereof. In another embodiment, a method of treating a subject is disclosed that includes obtaining a population of artery-derived brown adipose-like cells and administering the brown adipose-like cells into a target region in the subject. 1. Isolated artery-derived , ex vivo differentiated brown adipose-like cells.2. The brown adipose-like cells of further characterized by expression of at least one adipocyte marker selected from fatty acid binding protein 4 (aP2) claim 1 , peroxisome proliferator activated receptor α (PPARα) peroxisome proliferator activated receptor γ (PPARγ) claim 1 , adiponectin (ADN) claim 1 , uncoupling protein 1 (UCP-1) claim 1 , PR domain containing protein 16 (PRDM16) claim 1 , PPAR coactivator-1α (PGC-1α) claim 1 , CCAAT/enhancer binding protein β (C/EBPβ) claim 1 , cell death-inducing DFFA-like effector A (CIDE-A) claim 1 , and elongation of very long chain fatty acids like protein 3 (ELOVL3).3. The brown adipose-like cells of claim 2 , wherein the adipocyte marker is a brown adipocyte marker selected from uncoupling protein 1 (UCP-1) claim 2 , PR domain containing protein 16 (PRDM16) claim 2 , PPAR coactivator-1α (PGC-1α) claim 2 , CCAAT/enhancer binding protein β (C/EBPβ) claim 2 , cell death-inducing DFFA-like effector A (CIDE-A) claim 2 , and elongation of very long chain fatty acids like protein 3 (ELOVL3).4. The brown adipose-like cells ...

METHODS AND COMPOSITIONS FOR THE CLINICAL DERIVATION OF AN ALLOGENIC CELL AND THERAPEUTIC USES

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR. 1. An isolated cell obtained from a subepithelial layer of a mammalian umbilical cord tissue capable of self-renewal and culture expansion;wherein the isolated cell expresses at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105; andwherein the isolated cell does not express at least three cell markers selected from the group consisting of CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.2. The isolated cell of claim 1 , wherein the isolated cell expresses CD29 claim 1 , CD73 claim 1 , CD90 claim 1 , CD166 claim 1 , SSEA4 claim 1 , CD9 claim 1 , CD44 claim 1 , CD146 claim 1 , and CD105.3. The isolated cell of claim 1 , wherein the isolated cell does not express CD45 claim 1 , CD34 claim 1 , CD14 claim 1 , CD79 claim 1 , CD106 claim 1 , CD86 claim 1 , CD80 claim 1 , CD19 claim 1 , CD117 claim 1 , Stro-1 claim 1 , and HLA-DR.4. The isolated cell of claim 1 , wherein the isolated cell is positive for SOX2.5. The isolated cell of claim 1 , wherein the isolated cell is positive for OCT4.6. The isolated cell of claim 1 , wherein the isolated cell is positive for SOX2 and OCT4.7. The isolated cell of claim 1 , wherein the wherein the isolated cell is capable of differentiation into a cell type selected from the group consisting of adipocytes claim 1 , chondrocytes claim 1 , osteocytes claim 1 , ...

ADIPOSE-DERIVED STEM CELLS AND LATTICES

The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures. 1. An isolated adipose-derived stem cell (ADSC).244-. (canceled)45. An isolated population of mammalian adipose-derived stem cells having a CD marker profile comprising(i) STRO-1,(ii) CD49d,(iii) any one or more of CD29, CD44, CD71, CD90, CD105/SH2 and SH3, and,(iv) low or undetectable levels of CD106,and can differentiate into two or more of cells or tissues of an endodermal phenotype.46. An isolated population of mammalian adipose-derived stem cells having a CD marker profile comprising(i) STRO-1,(ii) CD49d,(iii) any one or more of CD29, CD44, CD71, CD90, CD105/SH2 and SH3, and,(iv) low or undetectable levels of CD 106,and can differentiate into cells or tissue of an ectodermal, endodermal or mesodermal phenotypes, (i) wherein the ectodermal phenotype is selected from the group consisting of neurogenic, dermatogenic and neuralgliagenic cells, and (ii) wherein the mesodermal phenotype is selected from the group ...

Method for dental pulp cryopreservation

The present invention relates to a method for cryopreserving the pulp of a non-exfoliated deciduous tooth, comprising a step of making with a laser a hole into the tooth removed from its physiological seat on the tooth neck. After making the hole, the tooth is contacted with a cryopreserving agent and then cryofrozen. An object of the invention further consists in mesenchymal stem cells isolated from the pulp of a cryopreserved tooth according to the method of the invention.

Equine Amniotic Fluid-Derived Multipotent Stem Cells and a Method for Producing the Same

The present invention relates to equine amniotic fluid-derived multipotent stem cells (eAF-MSCs) and a preparation method thereof. More particularly, the present invention relates to equine amniotic fluid-derived multipotent stem cells which exhibit all negative immunological characteristics with respect to the human markers, CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P and CD200, and exhibit all positive immunological characteristics with respect to the human markers, CD44, CD90 and CD105, and have the ability to differentiate into ectoderm, mesoderm or endoderm-derived cells. 1. A method for preparing equine amniotic fluid-derived multipotent stem cells showing the following characteristics and being more homogeneous than those before culture , comprisingStep 1 of culturing stem cells isolated from equine amniotic fluid in EGM-2 (Endothelial cell Growth Medium-2); andStep 2 of recovering the cultured cells:(a) showing all negative immunological characteristics with respect to the human markers CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P and CD200, and showing all positive immunological characteristics with respect to the human markers CD44, CD90 and CD105;(b) having the ability to differentiate into ectoderm, mesoderm or endoderm-derived cells; and(c) having the ability to maintain an undifferentiated state for 14 passages or more.2. The method according to claim 1 , wherein the stem cells isolated from equine amniotic fluid in Step 1 are those isolated from a middle layer claim 1 , cell layer claim 1 , after centrifugation using a density-gradient solution.3. The method according to claim 1 , wherein the culturing of Step 1 is culturing of the stem cells isolated from equine amniotic fluid in attached plate with EGM-2 (Endothelial cell Growth Medium-2).4. The method according to claim 1 , wherein fetal bovine serum (FBS) is added to EGM-2 in Step 1.5. The method according to claim 1 , wherein the cells cultured in Step 1 are further ...

PROCESS OF APPLICATION PROCEDURES THROUGH CELL BIOLOGY FOR ANIMAL USE

Process of application procedures through cell biology for animal use, the invention is applied to the field of cell biology, specifically the isolation, in vitro culture, cryopreservation, cell differentiation and application of mesenchymal stem cells derived from adipose tissue of animals for autologous cell therapy purposes. Strategically seeks to establish, from the adipose tissue collection, all events resulting in schematic form, in order to obtain a homogeneous extract of mesenchymal stem cells. In this invention, it is proposed a dynamic which allows the use of mesenchymal stem cells in veterinary cell therapy found in centers distant from the cell culture laboratory, since the transportation time of tissue and mesenchymal stem cells does not exceeds 78 hours after the their processing. 1. Process of application procedures through cell biology for animal use , which applies to totipotent or multipotent cells , which are found in the early stages of the embryo (embryo button) , the fetus (mesoderm) , newborn (cord cord) and in adult individuals (at different sites such as bone marrow , adipose tissue , dental pulp , wherein the use of mesenchymal stem cells in cell therapy in veterinary laboratories , cell culture , establishing , from the collection of adipose tissue all events resulting in schematic form , in order to obtain a homogeneous extract from mesenchymal stem cells; applied to the isolation , in vitro culturing , cryopreservation , use of cell differentiation and mesenchymal stem cells from adipose tissue of animals for autologous cell therapy , and consists of the following steps: Preparation of Medium for Collection of Adipose Tissue , Mounting of the kit for Adipose Tissue Collection , Preparation of medium for isolation of stem cells from the Adipose Tissue; Preparation of the MSC-AD;{'b': 1', '0, 'Preparation of the Digest medium; Preparation of the Erythrolysis medium; Reception, washing and maceration of adipose tissue; Reception of the ...

HUMAN ADIPOCYTE-DERIVED BASEMENT MEMBRANE FOR TISSUE ENGINEERING APPLICATIONS

The present disclosure generally relates to tissue engineering. More particularly, the present disclosure relates to the generation of a new biologically active and biocompatible human derived materials useful in tissue engineering applications. 1. A method comprising:differentiating preadipocytes;culturing the differentiated preadipocytes in media;collecting the extracellular matrix proteins secreted by the preadipocytes;filtering the extracellular matrix proteins; andcollecting retentate from said filtering.2. The method of claim 1 , wherein the retentate is a gel.3. The method of claim 1 , further comprising using the retentate as a scaffold.4. The method of claim 1 , wherein the retentate comprises extracellular matrix proteins larger than 100 kDa.5. The method of claim 1 , further comprising using the retentate to promote cell adhesion.6. The method of claim 1 , wherein collecting the extracellular matrix proteins secreted by the preadipocytes comprises collecting the media in which the preadipocytes are cultured.7. The method of claim 1 , wherein filtering the extracellular matrix proteins comprises using a centrifuge filter.8. The method of wherein the retentate comprises extracellular matrix proteins and growth factors.9. The method of claim 1 , further comprising culturing islet cells in the presence of the retentate.10. The method of claim 1 , wherein the media comprises at least one of rosiglitazone claim 1 , proline claim 1 , osteocalcin claim 1 , hydroxyproline claim 1 , oleic acid claim 1 , palmitic acid claim 1 , and linoleic acid.11. The method of wherein the preadipocytes are Simpson-Golabi-Behmel Syndrome preadipocytes. Tissue and organ replacement has been limited to either transplantation with donor tissue or more recently, replacement with synthetic biomedical devices. However, both strategies suffer from significant disadvantages. Transplantation is limited by the number of healthy organ donors as well as viability of donated organs. While ...

SYSTEMS AND METHODS FOR MANIPULATION OF REGENERATIVE CELLS FROM ADIPOSE TISSUE

The invention provides methods for manipulating regenerative cells from adipose tissue. Specifically, it provides methods for enrichment of desired cells and enhancement of their therapeutic effects. 1. A method for processing regenerative cells from adipose tissue comprising:(a) introducing adipose tissue into a tissue collection container of a device configured to harvest regenerative cells from adipose tissue, while maintaining a closed, sterile fluid/tissue pathway;(b) reducing the presence of free lipids and peripheral blood elements from said adipose tissue in the tissue collection container;(c) disaggregating said adipose tissue in the tissue collection container to generate a cell suspension;(d) separating the regenerative cells from the acellular component in the suspension;(e) concentrating the regenerative cells; and(f) manipulating the regenerative cells to obtain processed regenerative cells, wherein the manipulation is selected from the group consisting of exposure to hypoxic conditions, exposure to hyperoxic conditions, exposure to UV light, exposure to infared light, exposure to ultrasonic stimulation, and exposure to electrical stimulation.2. The method of claim 1 , further comprising delivering the processed regenerative cells to a patient.3. The method of claim 1 , further comprising heating or cooling the regenerative cells.4. The method of claim 1 , wherein the separating comprises density gradient centrifugation claim 1 , or continuous flow centrifugation claim 1 , or both.5. The method of claim 1 , wherein the separating comprises adhering sample components to a solid phase surface.6. The method of claim claim 1 , wherein the solid phase surface is selected from the group consisting of tissue culture plastic claim 1 , plastic beads claim 1 , glass beads claim 1 , and scaffolds or any combination thereof.7. The method of claim 1 , further comprising exposing the regenerative cells to an additive.8. The method of claim 7 , wherein the additive ...

Brown Adipocyte Progenitors in Human Skeletal Muscle

Brown adipose tissue (“BAT”) progenitor cells and methods for identifying BAT progenitor cells in a population of cells are provided. Methods are also provided for inducing differentiation of BAT progenitor cells into differentiated brown adipocytes, inducing expression or increased activity levels of BAT uncoupling protein-1 (“UCP1”), and for identifying agents capable of inducing differentiation of BAT progenitor cells into brown adipocytes and/or inducing expression or increased activity levels of UCP1. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for treatment of or the making of medicaments for the treatment of metabolic diseases or conditions in a patient such as obesity, overweight, impaired glucose tolerance, insulin-resistance, type 2 diabetes, dyslipidemia, hypertension, cardiovascular diseases, metabolic syndrome, and the like. Differentiated brown adipocytes and agents and methods for inducing differentiation of BAT progenitor cells can be used for prevention of hypothermia. 14-. (canceled)5. A method for inducing differentiation of brown adipose tissue (BAT) progenitor cells into brown adipocytes comprising:providing a BAT progenitor cell isolated from skeletal muscle; andexposing the BAT progenitor cell to a differentiation medium;wherein the differentiation medium induces the BAT progenitor cell to differentiate into a brown adipocyte.6. The method of wherein the differentiation medium comprises one or more of the following: a PPARγ activator claim 5 , modulator or inhibitor; a PPARα activator or modulator; a PPARδ activator or modulator; a dual PPARα and PPARδ activator or modulator claim 5 , a pan-PPAR (α claim 5 , β claim 5 , γ) activator or modulator; a PDE4 inhibitor; a PDE7 inhibitor claim 5 , a NRIP1 (RIP140) inhibitor claim 5 , a PTEN inhibitor; an α1-adrenergic full or partial agonist; an RXRα activator or modulator; a PGC-1αactivator; a PGC-1 inhibitor or activator ...

APPARATUS AND METHODS FOR CELL ISOLATION

A unitary apparatus for isolating cells from adipose tissue including a lipid separation processor with a dispersing head equipped with a plurality of ports and a digestion chamber for dissociation of the constituent cells disposed in adipose tissue. The lipid separating apparatus is useful for the separation of lipids and adipocytes from a mixed cell population. A cell seeding chamber may be attached to the cell isolation apparatus. The components of the apparatus may be packaged in modular kit form. 1a digestion chamber having at least one inlet port and at least one outlet port and adapted for separation of adipose tissue across a digestion mesh during enzymatic dissociation of the adipose tissue into a dissociated cell mixture;a lipoaspirate port on the digestion chamber and adapted for removal of lipoaspirate or washed lipoaspirate prior to enzymatic dissociation of the adipose tissue;a dispersing filter having an inlet port and an outlet port and in fluid communication with the digestion chamber and configured to filter the dissociated cell mixture into a dispersed cell mixture; anda lipid separating unit including at least one dispersing head having a plurality of pores in fluid communication with an outlet port of the dispersing filter, wherein lipid separating unit is adapted for fluid phase separation of lipids and adipocytes from the dispersed cell mixture.. A sterile disposable apparatus for preparation of lipoaspirate and isolation of cells from adipose tissue comprising: This application is a continuation of U.S. application Ser. No. 12/746,334, filed Jun. 4, 2010, which is the United States National Phase Application of International Application No. PCT/US2008/085407, filed Dec. 3, 2008, and claims priority based on U.S. Provisional Application No. 61/005,267, filed Dec. 4, 2007, and U.S. Provisional Application No. 61/091,687, filed Aug. 25, 2008, entireties of which are incorporated herein by reference.This invention relates generally to apparatus ...

Brown Fat Cell Compositions and Methods

Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes. 116-. (canceled)17. A method of differentiating a stem cell into a brown fat cell , the method comprising: contacting a stem cell with a medium not comprising an animal product , thereby generating a brown fat stem cell.18. The method of claim 17 , wherein the medium comprises an agent selected from the group consisting of: insulin claim 17 , dexamethasone claim 17 , isobutylmethylxanthine claim 17 , indomethacin claim 17 , T3 claim 17 , rosiglitazone claim 17 , FNDC5 and combinations thereof.19. The method of claim 17 , wherein the medium comprises insulin claim 17 , dexamethasone claim 17 , isobutylmethylxanthine claim 17 , and indomethacin.20. The method of claim 17 , wherein the brown fat stem cell expresses PRDM-16 claim 17 , PGC-1 claim 17 , or a combination thereof.21. The method of claim 17 , wherein the brown fat tissue is from a sample obtained from a subject. This application claims priority to and benefit of U.S. Provisional application 61/502,508 filed on Jun. 29, 2011, U.S. Provisional application 61/632,122 filed on Jan. 18, 2012, and U.S. Provisional application 61/632,516 filed on Jan. 25, 2012 the entirety of each of these applications is incorporated by reference herein.This invention relates to the field of cell culture and more specifically to the culture and use of stem cells.Brown fat is one of two types of adipose tissue found in the human body. During embryogenesis, brown fat is derived from the differentiation of the mesoderm. Brown fat is involved in development and homeostasis by providing metabolic tissue capable of ...

CULTURE METHOD, GROUP OF MATURE ADIPOCYTES, DRUG SCREENING METHOD

In a culture method for adipocytes, seeded adipocytes are cultured while being allowed to adhere to a culture bottom surface () and walls () disposed perpendicularly to the culture bottom surface (), without suspending the adipocytes in a culture solution, thereby obtaining mature adipocytes in which spherical lipid droplets having increased in size are generated within cells. This method uses a culture chamber () in which the walls () are formed perpendicular to the culture bottom surface (). Spherical mature adipocytes containing spherical lipid droplets having increased in size within cells are cultured in a state where a cell or an aggregate of cells is allowed to adhere to two or more locations on the walls () and the culture bottom surface (), thereby obtaining adipocytes having a shape similar to that of adipocytes in vivo. 1. A culturing method for adipocytes , the method comprising providing cultured adipocytes in a culture chamber , without suspending the adipocyte in a culture solution , to obtain spherical mature adipocytes in which spherical lipid droplets having increased in size are stored ,wherein:the culture chamber comprises a culture bottom surface and walls disposed perpendicularly to the culture bottom surface; andthe cultured adipocytes are adhered to the culture bottom surface and to the walls.2. The culture method according to claim 1 , wherein the cultured adipocytes contain lipid droplets of less than 0.5×10μm.3. The culture method according to claim 1 , wherein the cultured adipocytes are adipocytes differentiated from bone-marrow stromal cells claim 1 , mesenchymal stem cells claim 1 , embryonic stem cells claim 1 , or induced pluripotent stem cells.4. The culture method according to claim 1 , wherein the cultured adipocytes are preadipocytes.5. The culture method according to claim 4 , further comprising differentiation-inducing the preadipocytes after the preadipocytes are proliferated to a 90% confluent state.6. The culture method ...

METHODS OF TREATING TISSUE VOIDS FOLLOWING REMOVAL OF IMPLANTABLE INFUSION PORTS USING ADIPOSE TISSUE PRODUCTS

Compositions and methods for treating tissue are provided. The compositions may include tissue matrix derived from adipose tissue suitable for injection, small-volume implantation, or use as a soft-tissue regenerative material. Also provided are methods for producing such compositions. 1. A method for treating a void in soft tissue comprising:removing an implanted infusion port from an anatomic location of a subject to create a void through a skin incision;delivering a flowable composition comprising an adipose-based tissue matrix into the void at a time proximate to the removing step; andclosing the skin incision.2. The method of claim 1 , wherein the composition is delivered before closing the incision.3. The method of claim 1 , wherein the composition is delivered after closing the incision.4. The method of claim 1 , wherein the anatomic location is an anterior chest wall.5. The method of claim 1 , wherein the delivering step comprises injecting the flowable composition through a needle inserted percutaneously.6. The method of claim 1 , wherein the delivering step comprises placement of the composition into the soft tissue dead space through an open surgical incision.7. The method of claim 1 , wherein the composition comprises a carrier that prevents dissipation of the adipose-based tissue matrix away from the void.8. The method of claim 1 , wherein the composition further comprises a glycosaminoglycan.9. The method of claim 8 , wherein the glycosaminoglycan is hyaluronic acid.10. The method of claim 9 , wherein the hyaluronic acid is a non-crosslinked hyaluronic acid.11. The method of claim 9 , wherein the hyaluronic acid is a crosslinked hyaluronic acid.12. The method of claim 9 , wherein the hyaluronic acid is present in the composition at a concentration by weight of about 2.5%.13. The method of claim 1 , wherein the composition comprises a local anesthetic.14. The method of claim 1 , wherein the adipose-based tissue matrix is in the form of a suspension of ...

BROWN ADIPOCYTE MODIFICATION

Methods and therapeutics are provided for treating metabolic disorders by increasing activation of brown adipose tissue. Generally, the methods and therapeutics can increase activation of brown adipose tissue to increase energy expenditure and induce weight loss. In one embodiment, a method for increasing activation of brown adipose tissue includes modifying brown adipocytes to express a gene that activates brown adipocytes, such as uncoupling protein 1. In another embodiment, a method for increasing brown adipose tissue activation includes increasing the number of brown adipocytes. This can be accomplished by inducing proliferation of adipocytes in vivo or expanding adipocytes ex vivo, transplanting adipocytes into brown adipose tissue depots or elsewhere and inducing differentiation of adipocyte progenitor cells, such as MSCs, adipocyte progenitor cells, pre-adipocytes and adipocyte precursor cells. 1. A method of modifying brown adipose tissue , the method comprising:altering at least one brown adipocyte by expressing a vector capable of modulating signaling, thereby, affecting uncoupling protein activity, wherein modulating the uncoupling protein signaling alters adipocyte activation.2. The method of claim 1 , wherein the vector comprises a gene for a receptor claim 1 , optionally wherein the receptor is selected from the group consisting of thyroid hormone receptor (TR) claim 1 , peroxisome proliferators-activated receptor (PPAR) claim 1 , β-adrenergic receptor claim 1 , transforming growth factor receptor claim 1 , free fatty acid receptor and low density lipoprotein receptor.3. (canceled)4. The method of claim 2 , wherein the receptor is a hybrid receptor claim 2 , optionally wherein the hybrid receptor comprises at least a portion of a receptor selected from the group consisting of thyroid hormone receptor (TR) claim 2 , peroxisome proliferators-activated receptor (PPAR) claim 2 , β-adrenergic receptor claim 2 , transforming growth factor receptor claim 2 , ...

METHOD FOR PREPARING TISSUE, PARTICULARLY ADIPOSE TISSUE, FOR TRANSPLANTATION FROM LOBULAR FAT EXTRACTED BY LIPOSUCTION

A method of preparing adipose tissue for transplantation, from lobular fat extracted, for instance, by liposuction, said fat consisting of a fluid component comprising an oily component, a blood component and/or sterile solutions and of a solid component comprising cell fragments, cells and one or more cell macroagglomerates of heterogeneous size, characterized in that it includes at least one step of washing the cell aggregates carried out at the same time as a step of separating the fluid component, in emulsion form, from the solid component. 1. A method of preparing adipose tissue for transplantation from lobular fat material extracted from a body by liposuction , said fat material comprising (a) a fluid component comprising one or more of an oily component , a blood component and sterile solutions , and (b) a solid component comprising cell fragments , cells and one or more cell macroagglomerates of heterogeneous size , said method comprisingwashing the solid component at least once, and separating the fluid component, in emulsion form, from the solid component, wherein said washing and separating steps are carried out at the same time, and wherein said washing and separating steps include:injecting at least one sterile washing solution into a washing chamber containing the fat material, of a washing and separating container, wherein the washing chamber contains an outlet and at least one stirring element;manually or mechanically stirring said washing and separating container to facilitate the emulsion of the fluid components;arranging the washing and separating container in a vertical position relative to the ground, with the outlet facing downwards, to obtain a stratification of the solid components on the liquid emulsion, which constitutes the fat material contained in the washing chamber, which results in a solid component, composed of cell fragments, cells and one or more cell agglomerates, floating on an emulsion of the fluid components that are present in ...

CELL SEPARATION APPARATUS

Systems and methods herein are directed towards the separation of biologic material to obtain a target cell volume and/or cell concentration for harvesting. The target volume and/or concentration of cells may be obtained through a single cycle via three chambers, or by repeated cycles through one or more chambers to dilute the digestive enzymes used in the process and concentrate the harvestable cell volume to a predetermined target. 1. A system for obtaining a target cell volume , comprising:a first chamber comprising a first separation mechanism and configured to separate a volume of biological material into a first retained volume and a first transfer volume; receive the first transfer volume from the first chamber and', 'separate, in response to receiving the first transfer volume, a second transfer volume and a second retention volume from the first transfer volume;, 'a second chamber in fluid communication with the first chamber and configured to receive the second transfer volume; and', 'separate a third transfer volume and a waste volume from the second transfer volume;, 'a third chamber comprising a first side and a second side, wherein the first side is in fluid communication with the second chamber and configured toa pump in fluid communication with at least the third chamber, wherein the pump is configured in a first state to establish a horizontal flow of the second transfer volume from the first side of the third chamber to the second side of the third chamber;a waste collection repository in fluid communication with the second side of the third chamber via a first coupling and configured to receive the waste volume; anda product collection repository in fluid communication with the second side of the third chamber via a second coupling and configured to receive the third transfer volume, wherein the third transfer volume comprises a predetermined volume of cells and fluid.2. The system of claim 1 , wherein the first separation mechanism comprises a ...

METHODS FOR IN SITU CELL SODDING

Cell delivery matrices and methods for facilitating local delivery of adipose derived endothelial cells to a target tissue, body cavity, or joint are described. The cell delivery matrix may be a three-dimensional matrix scaffold comprising fibrin derived from the patient's own body. The cell delivery matrix may be biocompatible and semi-permeable. The cell delivery matrix used in the methods of the invention may be comprised of any degradable, bioabsorbable or non-degradable, biocompatible polymer. Regenerative therapies comprising implanting in the subject cell delivery matrices localizing adipose derived endothelial cells are described. The cell delivery matrices maintain the adipose derived endothelial cells at the target for a therapeutically effective amount of time. The adipose derived endothelial cells can be allogenic or syngenic to the subject. The endothelial cells may be delivered alone or in combination with other therapeutic agents. 1. A method of delivering and maintaining stem cells at the lumenal surface of a tubular tissue , comprising:providing a collecting vessel for processing tissue to produce an endothelial cell product, the vessel having a rinsing and digesting chamber in fluid communication with a separate waste chamber and an isolation chamber connected to the rinsing and digesting chamber, wherein a screen separates at least the rinsing and digesting chamber and the waste chamber;introducing tissue to be processed into the rinsing and digesting chamber;introducing rinsing solution into the rinsing and digesting chamber;orienting the vessel to screen the tissue to be processed of rinsing solution passed into the waste chamber;introducing an enzyme into the rinsing and digesting chamber;heating the tissue and the enzyme for a sufficient time and temperature while agitating the rinsing and digesting chamber to digest the tissue with the enzyme;centrifuging the vessel to transfer cells from the digested tissue from the rinsing and digesting ...

METHOD FOR PROMOTING DIFFERENTIATION OF CULTURED CELLS AND CULTURED CELL DIFFERENTIATION-PROMOTING AGENT

The invention is a method for promoting differentiation of cultured cells, including bringing a norbornene-based addition polymer formed article into contact with cells being cultured, and a cultured cell differentiation-promoting agent including a norbornene-based addition polymer formed article. The invention provides a method that can further promote the differentiation of cultured cells, and a cultured cell differentiation-promoting agent that may suitably be used for the method. 1. A method for promoting differentiation of cultured cells , including bringing a norbornene-based addition polymer formed article into contact with cells being cultured.2. The method for promoting differentiation of cultured cells according to claim 1 , wherein the cells that are being cultured are stem cells.3. The method for promoting differentiation of cultured cells according to claim 2 , wherein the cells that are being cultured are adipose-derived stem cells.4. A cultured cell differentiation-promoting agent including a norbornene-based addition polymer formed article. The present invention relates to a method for promoting the differentiation of cultured cells, and a cultured cell differentiation-promoting agent.In recent years, regenerative medicine that utilizes pluripotent cells and stem cells (e.g., ES cells and iPS cells) and mesenchymal stem cells has attracted attention. Pluripotent cells and stem cells are said to be undifferentiated cells that have not differentiated. According to regenerative medicine, these undifferentiated cells are caused to differentiate into the desired internal organ, tissue, or cells, and the patient is treated using the resulting internal organ, tissue, or cells. For example, adipose-derived stem cells sampled from subcutaneous adipose tissues of a patient can be differentiated into adipocytes through preadipocytes, or differentiated into osteocytes or chondrocytes by differentiation induction culture. Orthopaedic surgical treatment and ...

TISSUE PROCESSING APPARATUS WITH FLUID SUCTION FEATURES AND METHODS RELATING TO COLLECTING AND PROCESSING HUMAN BIOLOGICAL MATERIAL

A portable apparatus for collection and processing of human biological material containing adipose, such as extracted during a lipoplasty procedure, is useful for multi-step processing to prepare a concentrated product (e.g., stromal vascular fraction) or a fat graft composition. The apparatus has a container with an internal containment volume with a tissue retention volume and a filtrate volume separated by a filter and with a tapered portion to a collection volume for collecting concentrate product. The apparatus has fluid suction features including a suction port and a conduit providing fluid communication from the suction port to a location within the filtrate volume within a tapered portion of the internal containment volume, and optionally including a second suction port and a second conduit to a different location in the filtrate volume with the second conduit being configured to permit elevation adjustment within the filtrate volume. Methods include use of the fluid suction features during collection of human biological material and/or post collection. 1. An apparatus for collection of human biological material and post-collection processing of collected material , the apparatus being orientable in a collection orientation for collection of human biological material , as oriented in the collection orientation the apparatus comprising:a filter; a tissue retention volume and a filtrate volume separated by the filter;', 'a collection volume within the filtrate volume, the collection volume having a bottom elevation corresponding to a bottom elevation of the filtrate volume and a top elevation that is lower than the bottom elevation of the tissue retention volume;', 'a tapered portion that tapers in a downward direction with at least a portion of the tapered portion being located above the collection volume;, 'a container having an internal containment volume, the internal containment volume comprisingan inlet port in fluid communication with the tissue ...

Apparatus for Preconditioning of Cell Suspensions

An apparatus for the preparation of cells for implantation into a living body is disclosed. The apparatus comprises a vessel substantially impermeable to gaseous oxygen; and fluid within said vessel, the fluid having a maximal dissolved oxygen capacity substantially equivalent to normal saline yet having a hypoxic oxygen concentration between about 0% to about 5% of said maximal dissolved oxygen capacity. The bag oxygen concentration level remains low when the apparatus is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days. The present invention simplifies the process of achieving donor cell hypoxic preconditioning for cell implantation, and may be used to bathe said cells to be transplanted for a sufficient time to activate the hypoxic metabolic pathway. 1. A method for the preparation of mammalian cells for implantation into a living body , the method comprising the steps of: i. a first vessel substantially impermeable to gaseous oxygen;', 'ii. hypoxic fluid within said first vessel, the hypoxic fluid having a maximal dissolved oxygen capacity and having an oxygen concentration level of not more than 5% of said maximal dissolved oxygen capacity; and', 'iii. a mammalian cell retaining chamber comprising a filter and mammalian cells having a level of HIF-1α; and, 'a. providing an apparatus comprisingb. contacting said hypoxic fluid with said mammalian cells within said filter.2. The method of wherein said oxygen concentration level is between 0.05% and 1.5% of said maximal dissolved oxygen capacity.3. The method of wherein said hypoxic fluid within said first vessel maintains said oxygen concentration level when said first vessel is stored at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days.4. The method of further comprising storing said first vessel at 22°-25° C. in normal atmospheric conditions for a period of at least 30 days such that said oxygen concentration of not more than 5% of said maximal ...

METHOD FOR EXTENDING TELOMERE OF CELL

A method for elongating telomeres of cells comprises steps of: providing physical stimulation directly or indirectly to cells; and culturing a mixture of the cells and a medium for a predetermined time, wherein providing the stimulation directly to the cells comprises applying physical stimulation to the medium containing the cells, and providing the stimulation indirectly to the cells comprises applying physical stimulation to the medium not containing the cells and then mixing the medium and the cells. The method for elongating telomeres of cells is simpler than a conventional method and is superior in terms of time, cost, efficiency, and safety. In addition, the method induces cell division and provides an anti-aging effect, in addition to simply elongating telomeres. Thereby, it is expected that the method can ameliorate and prevent not only problems caused by shortening of telomeres, but also various aging-related diseases and conditions. 1. A method for elongating telomeres of cells , the method comprising steps of:providing physical stimulation directly or indirectly to the cells; andculturing a mixture of the cells and a medium for a predetermined time,wherein the providing the stimulation directly to the cells is applying the physical stimulation to a medium containing the cells, and the providing the stimulation indirectly to the cells is applying the physical stimulation to the medium not containing a cells and then mixing the medium and the cells.2. The method of claim 1 , wherein a form of the physical stimulation is any one selected from among ultrasound claim 1 , heat claim 1 , and light.3. The method of claim 1 , wherein the step of providing the physical stimulation directly or indirectly to the cells is performed by any one method selected from among:a method of mixing the cells and the medium and then providing the physical stimulation to the mixture; ora method of providing the physical stimulation to a medium and then mixing the medium and the ...

METHOD FOR ISOLATING STEM CELLS FROM HUMAN UMBILICAL CORD

The present invention relates to a method for isolating umbilical cord-derived stem cells, and more specifically to a method for isolating a significantly large number of mesenchymal stem cells from the umbilical cord having a specified size. The method of the present invention has a great advantage in that since stem cells can be isolated from an umbilical cord tissue without enzymatic treatment, stress applied to the cells can be significantly suppressed. In addition, stem cells obtained by the method of the present invention have superior proliferative capacity compared to stem cells obtained by conventional isolation methods. 1. A method for isolating umbilical cord-derived stem cells comprising (a) grinding an isolated umbilical cord tissue into explants having a width of 2 to 4 mm and a length of 2 to 4 mm and (b) culturing the explants in a culture medium.2. The method according to claim 1 , wherein step (a) comprises introducing an umbilical cord tissue into a culture medium and chopping the umbilical cord tissue into explants having a width of 2 to 4 mm and a length of 2 to 4 mm.3. The method according to claim 2 , wherein the culture medium is added in an amount of 0.5 to 3.0 ml per gram of the umbilical cord tissue.4. The method according to claim 1 , wherein the culture medium is selected from the group consisting of Dulbecco's minimum essential medium (DMEM) claim 1 , RPMI claim 1 , Ham's F-10 claim 1 , Ham's F-12 claim 1 , α-minimal essential medium (α-MEM) claim 1 , Glasgow's minimal essential medium (GMEM) claim 1 , Iscove's modified Dulbecco's medium (IMDM) claim 1 , and combinations thereof.5. The method according to claim 1 , wherein the explants are cultured to reach 0.0007 to 0.0068 g per unit area (cm).6. The method according to claim 1 , wherein step (b) is carried out for 60 to 120 minutes. The present invention relates to a method for isolating umbilical cord-derived stem cells, and more specifically to a method for isolating a significantly ...

NOVEL MUSCULOSKELETAL STEM CELL

The present disclosure relates to a novel musculoskeletal stem cell (MSSC) differentiated from an ESC (embryonic stem cell) or an iPSC (induced pluripotent stem cell). The musculoskeletal stem cell of the present disclosure can be easily induced from a human embryonic stem cell or a human-derived pluripotent stem cell and can be effectively differentiated not only into bone but also into cartilage, tendon and muscle. Accordingly, it can be usefully used for prevention or treatment of various musculoskeletal diseases. 1. A medium composition for inducing differentiation into a musculoskeletal stem cell (MSSC) , comprising noggin , LIF (leukemia inhibitory factor) , bFGF (basic fibroblast growth factor) , CHIR99021 (9-bromo-7 ,12-dihydro-pyrido[3′ ,2′:2 ,3]azepino[4 ,5-b]indol-6(5H)-one) as Wnt signaling activator , PD0325901 (N-[(2R)-2 ,3-dihydroxypropoxy]-3 ,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-benzamide) as ERK (extracellular signal-regulated kinase) signaling inhibitor and SB431542 (4-[4-(1 ,3-benzodioxol-5-yl)-5-(2-pyridinyl)-1H-imidazol-2-yl]benzamide) as TGF-β/activin/nodal signaling inhibitor ,wherein the musculoskeletal stem cell can be differentiated into bone, cartilage, tendon, ligament, muscle and fat.24-. (canceled)5. A method for preparing a musculoskeletal stem cell claim 1 , comprising a step of culturing an ESC (embryonic stem cell) or an iPS (induced pluripotent stem cell) in the medium composition for inducing differentiation into a musculoskeletal stem cell according to .6. The method for preparing a musculoskeletal stem cell according to claim 5 , wherein the culturing is performed for 5 passages or longer without change in the composition of the medium.7. A musculoskeletal stem cell prepared using the medium composition for inducing differentiation into a musculoskeletal stem cell according to .8. A musculoskeletal stem cell (MSSC) differentiated from an ESC (embryonic stem cell) or an iPSC (induced pluripotent stem cell) claim 1 , ...

INDUCING BROWN FAT FATE AND FUNCTION

Methods and compositions are described herein for generating brown adipose cells and tissues that involve contacting one or more starting cells with bexarotene, ciclopirox, IOX2, or combinations thereof. When administered in vivo, subjects receiving bexarotene, ciclopirox, IOX2, or combinations thereof have reduced white adipose tissue mass (with enhanced beige features) as well as enlarged brown fat tissue compared to a control mammal that did not receive the bexarotene, ciclopirox, IOX2, or combinations thereof. The subjects also have increased energy expenditure, generate more heat, and/or consume more oxygen, than a control mammal that did not receive the bexarotene, ciclopirox, IOX2, or combinations thereof. 1. A method of generating brown adipose cells from non-brown adipose starting cells , comprising contacting the starting cells with bexarotene , ciclopirox , IOX2 , or combinations thereof , to thereby generate brown adipose cells.2. The method of claim 1 , wherein the starting cells are selected from the group of myoblasts claim 1 , adipocytes claim 1 , pre-adipocytes claim 1 , mesenchymal precursor cells claim 1 , multipotent stem cells claim 1 , pluripotent stem cells claim 1 , unipotent stem cells claim 1 , fibroblasts claim 1 , white adipocytes claim 1 , and any combination thereof.3. The method of claim 1 , which inhibits white adipocyte cell generation.4. The method of claim 1 , further comprising contacting the one or more starting cells with retinoic acid claim 1 , 9-cis retinoic acid claim 1 , all-trans 3 claim 1 ,4-didehydro retinoic acid claim 1 , 4-oxo retinoic acid claim 1 , retinol claim 1 , rosigliotazone claim 1 , forskolin claim 1 , or any combination thereof.6. The method of claim 1 , performed in vitro.7. The method of claim 6 , further comprising administering the one or more brown adipose cells to a mammal.8. The method of claim 1 , performed in vivo.9. The method of claim 8 , wherein the bexarotene claim 8 , ciclopirox claim 8 , IOX2 ...

Therapeutics Using Adipose Cells and Cell Secretions

The invention relates to compositions comprising (i) adipose tissue-derived cell secretions or (ii) an adipose tissue-derived cell suspension, optionally comprising adipocytes, or (iii) a combination of adipose tissue-derived cell secretions and an adipose tissue-derived cell suspension, optionally comprising adipocytes, and to their use in pharmaceutical compositions and methods for treatment of various conditions. The invention also relates to improved methods, agents and compositions for cryopreservation of cells.

METHODS FOR CELL EXPANSION AND USES OF CELLS AND CONDITIONED MEDIA PRODUCED THEREBY FOR THERAPY

A method of cell expansion is provided. The method comprising culturing adherent cells from placenta or adipose tissue under three-dimensional culturing conditions, which support cell expansion. 141-. (canceled)42. A method for preparing a pharmaceutical composition , comprisingintroducing adherent stromal cells (ASC) into a growth medium containing a plurality of 3D carriers, wherein the 3D carriers comprise an adherent material selected from the group consisting of a polyester, a polyalkylene, a polyfluorochloroethylene, a polyvinyl chloride, a polystyrene, and a polysulfone,incubating the growth medium containing the 3D carriers in a bioreactor, andremoving the ASC from the 3D carriers,thereby preparing a pharmaceutical composition.43. The method of claim 42 , wherein the 3D carriers are submerged in the growth medium.44. The method of claim 42 , wherein the 3D carriers are suspended in the growth medium.45. The method of claim 42 , wherein the 3D carriers are microcarriers.46. The method of claim 42 , wherein the 3D carriers comprise a non-woven fibrous matrix.47. The method of claim 42 , wherein the 3D carriers are packed in the bioreactor.48. The method of claim 42 , whereby the ASC are expanded on the 3D carriers.49. The method of claim 42 , wherein the ASC adhere to the 3D carriers.50. The method of claim 42 , wherein the ASC are in the form of a cell suspension in the pharmaceutical composition.51. The method of claim 42 , wherein the 3D carriers comprise polystyrene.52. The method of claim 42 , wherein the 3D carriers substantially consist of polystyrene.53. The method of claim 42 , wherein the surface of the 3D carriers comprises the adherent material.54. The method of claim 53 , wherein the adherent material is polystyrene.55. The method of claim 42 , wherein the step of removing takes place in the bioreactor.56. The method of claim 42 , wherein the ASC are derived from bone marrow.57. The method of claim 42 , wherein the ASC are derived from cord blood. ...

ACELLULAR SOFT TISSUE-DERIVED MATRICES AND METHODS FOR PREPARING SAME

A composition including delipidated, decellularized adipose tissue and delipidated, decellularized fascial tissue is provided. The composition may further include exogenous tissuegenic cells, an exogenous growth-inductive substance, and/or a carrier. The composition is suitable for implantation into a living body in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, wound care procedures or other procedures of regenerative medicine. A method of preparing an acellular soft tissue-derived matrix from adipose tissue and fascial tissue is also provided. The method involves preparing a delipidated, decellularized adipose-derived matrix by delipidizing the adipose tissue and decellularizing the adipose tissue; preparing a delipidated, decellularized fascia-derived matrix by delipidizing the fascial tissue and decellularizing the fascial tissue; and combining the delipidated, decellularized adipose-derived matrix and the delipidated, decellularized fascia-derived matrix to produce said acellular soft tissue-derived matrix. The resulting Acellular soft tissue-derived matrix may be partially dried, substantially dried, or not dried. 1. A composition , comprising delipidated , decellularized adipose tissue and delipidated , decellularized fascial tissue.2. The composition of claim 1 , wherein said delipidated claim 1 , decellularized adipose tissue is substantially free of native nucleic acids claim 1 , or said delipidated claim 1 , decellularized fascial tissue is substantially free of native nucleic acids claim 1 , or both.3. The composition of claim 1 , further comprising exogenous tissuegenic cells.4. The composition of claim 1 , further comprising at least one exogenous growth-inductive substance.5. The composition of claim 1 , further comprising a carrier.6. The composition of claim 5 , wherein said carrier comprises a substance selected from the group consisting of an isotonic solution claim 5 , a sodium chloride solution claim 5 , a ...

Methods and Compositions for the Clinical Derivation of an Allogenic Cell and Therapeutic Uses

Various cells, stem cells, and stem cell components, including associated methods of generating and using such cells are provided. In one aspect, for example, an isolated cell that is capable of self-renewal and culture expansion and is obtained from a subepithelial layer of a mammalian umbilical cord tissue. Such an isolated cell expresses at least three cell markers selected from CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105, and does not express at least three cell markers selected from CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR. 1. A method of treatment , comprising;administering isolated cells to a subject to treat a medical condition selected from COPD, diabetes, ischemia, osteoarthritis, orthopedic damage, liver damage, chronic refractory angina, erectile dysfunction, herniated disks, congestive heart failure, asthma, emphysema, wounds, acute radiation syndrome, autoimmune disorders, ischemic organ beds, graft vs. host disease, or a combination thereof, wherein the isolated cells are obtained, without enzymes, from a subepithelial layer of a mammalian umbilical cord tissue capable of self-renewal and culture expansion;wherein the isolated cell expresses at least three cell markers selected from the group consisting of CD29, CD73, CD90, CD166, SSEA4, CD9, CD44, CD146, or CD105; andwherein the isolated cell does not express NANOG and at least five cell markers selected from the group consisting of CD45, CD34, CD14, CD79, CD106, CD86, CD80, CD19, CD117, Stro-1, or HLA-DR.2. The method of claim 1 , wherein the isolated cell expresses CD29 claim 1 , CD73 claim 1 , CD90 claim 1 , CD166 claim 1 , SSEA4 claim 1 , CD9 claim 1 , CD44 claim 1 , CD146 claim 1 , and CD105.3. The method of claim 1 , wherein the isolated cell does not express CD45 claim 1 , CD34 claim 1 , CD14 claim 1 , CD79 claim 1 , CD106 claim 1 , CD86 claim 1 , CD80 claim 1 , CD19 claim 1 , CD117 claim 1 , Stro-1 claim 1 , and HLA-DR.4. The method of claim 1 , ...

METHODS AND KITS FOR DIRECTING CELL ATTACHMENT AND SPREADING

The present disclosure provides methods, and related kits, for directing cell attachment and spreading on a substrate and inducing isotropic spreading of cells; provides methods, and related kits, for cell sorting; and further provides methods, and related kits, for guided induction of stem cell differentiation. 1. A method of directing cell attachment and spreading on a substrate , comprising:culturing a cell on a curved substrate in the presence of cell culture media, wherein attachment and spreading increases as the curvature of the substrate decreases.2. The method of claim 1 , wherein the curved substrate is selected from the group consisting of a convex substrate claim 1 , a concave substrate claim 1 , a spherical substrate claim 1 , an oval substrate claim 1 , an elliptical substrate claim 1 , and combinations thereof.3. The method of claim 2 , wherein the curved substrate is a spherical substrate claim 2 , wherein the attachment and spreading increases as the diameter of the spherical substrate increases.4. The method of claim 3 , wherein the spherical substrate comprises a diameter of between about 500 μm and about 6 mm claim 3 , wherein attachment and spreading is influenced in that both attachment and spreading increases as the diameter of the spherical substrate increases from about 500 μm to about 6 mm.5. The method of claim 1 , wherein the curved substrate comprises a coating selected from the group consisting of a cell adhesive claim 1 , a cell adhesion-promoter claim 1 , a cell repellent claim 1 , or a combination thereof6. A method of inducing isotropic spreading of cells claim 1 , comprising:culturing a cell on a curved substrate, the curved substrate immobilized on a material layer, wherein the cell isotropically spreads over the curved substrate and onto the material layer.7. The method of claim 6 , wherein the curved substrate is a spherical substrate.8. The method of claim 7 , wherein the spherical substrate comprises a diameter of between ...

METHODS AND KITS FOR GUIDED STEM CELL DIFFERENTIATION

The present disclosure provides methods, and related kits, for directing cell attachment and spreading on a substrate and inducing isotropic spreading of cells; provides methods, and related kits, for cell sorting; and further provides methods, and related kits, for guided induction of stem cell differentiation. 1. A method for guided induction of stem cell differentiation , comprising:culturing a stem cell on a curved substrate in the presence of cell culture media.2. The method of claim 1 , wherein the curved substrate comprises a coating selected from the group consisting of a cell adhesive claim 1 , a cell adhesion-promotor claim 1 , a cell repellent claim 1 , or a combination thereof.3. The method of claim 1 , wherein the curved substrate is selected from the group consisting of a convex substrate claim 1 , a concave substrate claim 1 , a spherical substrate claim 1 , an oval substrate claim 1 , an elliptical substrate claim 1 , and combinations thereof.4. The method of claim 1 , wherein the curved substrate is a spherical substrate.5. The method of claim 4 , wherein the spherical substrate comprises a diameter of between about 500 μm and about 4 mm.6. The method of claim 4 , wherein the spherical substrate comprises a diameter of between about 500 μm and about 2 mm.7. The method of claim 4 , wherein the spherical substrate comprises a diameter of between about 4 mm and about 6 mm.8. The method of claim 4 , wherein the spherical substrate comprises a diameter of between about 500 μm and about 6 mm.9. The method of claim 1 , wherein the stem cell is a mesenchymal stem cell.10. The method of claim 9 , wherein the cell culture media comprises osteocyte differentiation induction media claim 9 , whereby the stem cell differentiates into an osteocyte.11. The method of claim 9 , wherein the stem cell differentiates into an adipocyte.12. A kit for guided induction of stem cell differentiation claim 9 , comprising:a first reagent, wherein the first reagent comprises a ...

CELL PREPARATION METHOD

Provided is a method of preparing a somatic cell including converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing differentiation of the somatic cell other than the differentiated somatic cell in the presence of a TGF-β pathway inhibitor. 1. A method of generating a somatic cell comprising converting a differentiated somatic cell of a mammal to other somatic cell by culturing the differentiated somatic cell in a medium for inducing a somatic cell other than the aforementioned differentiated somatic cell in the presence of a TGF-β pathway inhibitor.2. The method according to claim 1 , wherein the TGF-β pathway inhibitor is a D4476 claim 1 , SB431542 claim 1 , LY2157299 claim 1 , SD208 or ALK5 inhibitor II.3. The method according to claim 1 , wherein the TGF-β pathway inhibitor is an ALK5 inhibitor II.4. The method according to claim 1 , wherein the fibroblast is converted to a mesenchymal cell.5. The method according to claim 1 , wherein the fibroblast or keratinocyte is converted to an osteoblast.6. The method according to claim 1 , wherein the fibroblast or peripheral blood mononuclear cell is converted to a white adipocyte.7. The method according to claim 1 , wherein the fibroblast or keratinocyte is converted to a brown adipocyte.8. The method according to claim 6 , wherein the medium for inducing differentiation of the somatic cell comprises a Peroxisome Proliferator-Activated Receptor-γ (PPAR-γ) agonist.9. The method according to claim 1 , wherein the fibroblast is converted to a chondrocyte.10. The method according to claim 1 , wherein the fibroblast is converted to a myoblast.11. The method according to claim 1 , wherein the fibroblast is converted to a Schwann cell.12. The method according to claim 1 , wherein the keratinocyte is converted to a urothelial cell.13. The method according to claim 1 , wherein the fibroblast is converted to a mesenchymal stem cell.1415-. ( ...

Generation of Brown Adipose Tissue (BAT) from Mesenchymal Cells

Methods of generating functional human brown adipocytes, comprising exposing human stem cells, progenitor cells, or white adipocytes to culture with an differentiation cocktail that comprises one or more browning agents (e.g., one or more macromolecular crowders), and optionally one or more adipogenic agents, are described, as are populations of human brown adipocytes generated by the methods, and uses for the populations. Methods of generating functional human brown adipocytes in an individual, such as by administering a pharmaceutical composition comprising an differentiation cocktail, are also described. 1. A method of generating functional human brown adipocytes from human stem cells or progenitor cells , comprising culturing the cells with a differentiation cocktail comprising one or more adipogenic agents and one or more browning agents , wherein the cells thereby differentiate into functional human brown adipocytes.2. The method of claim 1 , wherein the human stem cells or progenitor cells are:a) derived from a mesenchymal or mesodermal lineage;b) cells that are capable of differentiating into cells from a mesenchymal or mesodermal lineage; orc) cells comprise cells selected from adipose-derived stem cells, human embryonic stem cells (HES), induced pluripotent stem cells (iPS), human bone marrow mesenchymal stem cells (hbmMSCs), preadipocytes, or progenitor cells found in adipose tissue or in skeletal muscle.34.-. (canceled)5. The method of claim 1 , wherein the one or more adipogenic agent(s) is selected from insulin claim 1 , glucocorticoid or synthetic equivalent claim 1 , a cAMP enhancer claim 1 , or vitamin C.6. The method of claim 1 , wherein the browning agent(s):a) comprises one or more maromolecular crowders; orb) further comprises an agent selected from thyroid hormone, a PPARγ receptor agonist, a bone morphogenetic protein, a retinoid, a cardiac natriuretic peptide, a myokine, a fibroblast growth factor, a microRNA, a lactogen, an insulin-like ...

COMPOSITION FOR INDUCING BEIGE ADIPOCYTE DIFFERENTIATION CONTAINING EXOSOME DERIVED FROM STEM CELLS

The present disclosure relates to a composition for inducing differentiation into beige adipocytes, which contains an exosome derived from stem cells differentiating into beige adipocytes as an active ingredient, a pharmaceutical composition, a health functional food and a differentiation medium composition containing the composition and a method for inducing differentiation into beige adipocytes using the same. 1. A composition for inducing differentiation into beige adipocytes , comprising an exosome extracted from stem cells differentiating into beige adipocytes as an active ingredient.2. The composition for inducing differentiation into beige adipocytes according to claim 1 , wherein the induction of differentiation into beige adipocytes is induction of differentiation of stem cells into beige adipocytes or induction of transdifferentiation of white adipocytes into beige adipocytes.3. The composition for inducing differentiation into beige adipocytes according to claim 1 , wherein the stem cells differentiating into beige adipocytes are bone marrow stem cells claim 1 , umbilical cord stem cells or adipose-derived stem cells.4. The composition for inducing differentiation into beige adipocytes according to claim 3 , wherein the bone marrow stem cells claim 3 , umbilical cord stem cells or adipose-derived stem cells are human- claim 3 , animal- or plant-derived stem cells.5. A pharmaceutical composition comprising the composition according to .6. The pharmaceutical composition according to claim 5 , wherein the pharmaceutical composition is for treating or preventing a metabolic disease.7. The pharmaceutical composition according to claim 6 , wherein the metabolic disease is obesity or diabetes.8. A health functional food comprising the composition according to .9. The health functional food according to claim 8 , wherein the health functional food is for improving or preventing obesity or diabetes.10. A medium composition for inducing differentiation into beige ...

Placental Stem Cell Populations

The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.

SEBOCYTES, SEBOCYTE CELL LINES AND APPLICATIONS THEREOF

Adipose cells (sebocytes) are described, The invention especially relates to sebaceous gland cells and to a sebaceous gland cell line with the property of being continuously grown over many sub-cultures. The sebocytes are excellently suited for useful applications. 1. An immortalized sebocyte derived from a human.2. The sebocyte according to claim 1 , wherein it is derived from a human sebaceous gland cell.3. The sebocyte according to claim 2 , wherein the sebaceous gland cell is a facial sebaceous gland cell.4. The sebocyte according to claim 1 , wherein it is present in the form of a cell line.5. The sebocyte according to claim 1 , wherein it is immortalized by transfection of DNA.6. The sebocyte according to claim 1 , wherein it expresses a SV-40 large T antigen.7. The sebocyte according to claim 1 , wherein it exhibits features of a normal claim 1 , non-transfected and differentiating sebocyte.8. The sebocyte according to claim 1 , wherein its proliferation is modifiable by an antigen and/or a retinoid.9. The sebocyte according to claim 1 , wherein it is cloned.10. Human sebocyte cell line DSM ACC2383.11. Use of the sebocyte according to claim 1 , for diagnostic claim 1 , therapeutic or cosmetic preparations.12. Use of the sebocyte according to claim 1 , for the examination of the physiology or the pathophysiology of human or animal sebaceous gland.13. Use of the sebocyte according to for the examination of the origin of acne and/or seborrhoe and/or other diseases.14. Use of the sebocyte according to claim 13 , wherein the other diseases to be examined are dermal diseases in which the sebaceous gland function is involved or may be involved.15. Use of the sebocyte according to claim 1 , for the testing of anti-acne and/or anti-seborrhoe compounds or agents.16. Use of the sebocyte according to claim 1 , for the testing of compounds or agents against diseases.17. Use of the sebocyte according to claim 16 , wherein the diseases are dermal diseases in which the ...

ADIPOCYTE SHEET, THREE-DIMENSIONAL STRUCTURE THEREOF, AND METHOD FOR PRODUCING THE SAME

The present invention aims to provide an artificial tissue that can efficiently reproduce myocardial tissue function and that can be used in an actual implantation and produced by culturing. The present invention relates to a graft material for treating myocardial disease, the graft material including a cell sheet containing adipocytes. 117-. (canceled)18. A method for producing a graft material for treating heart disease comprising a cell sheet containing adipocytes , without using a scaffold , the method comprising the steps of:a) culturing a cell group containing adipocytes on a cell culture support coated with a temperature-responsive polymer whose upper critical solution temperature or lower critical solution temperature in water is 0 to 80° C., in a culture solution;b) bringing the temperature of the culture solution to the upper critical solution temperature or above or the lower critical solution temperature or below; andc) peeling off the cell group as a cell sheet from the cell culture support.19. The method according to claim 18 , further comprising step d) of adding an ascorbic acid or a derivative thereof to the culture solution before step c).20. The method according to claim 18 , comprising no step of protease treatment.21. The method according to claim 19 , comprising no step of protease treatment.22. The method according to any one of to claim 19 , wherein the temperature-responsive polymer is poly(N-isopropylacrylamide). The present invention relates to an adipocyte sheet and a three-dimensional structure thereof, which are applicable to the heart. More specifically, the present invention relates to a cell sheet containing adult adipocytes, applicable to the heart, and useful in the fields of medicine, biology, drug discovery, pharmaceuticals, and the like; a method for producing the same; and a method for using the same.Myocardial infarction is an irreversible damage (Non-Patent Literature 1). Ischemic heart diseases are the cause of 50% of all ...

Method of Tissue Harvesting

The present disclosure relates to a tissue collection apparatus. The tissue collection apparatus comprises a housing defining an inlet and an outlet, a first filter disposed within the housing, a second filter disposed within the housing, the second filter configured to isolate tissue particles of a desired size that pass through the first filter under the application of an aspiration force applied through the housing. A method of harvesting tissue is also disclosed. 1. A method of collecting tissue , comprising:injecting a biocompatible gel through a filter of a tissue collection device from a second (downstream) side of the filter, the biocompatible gel expelling tissue from the filter and mixing with the tissue upstream of a first (upstream) side of the filter to form a combination of the biocompatible gel and the tissue; andcollecting the combination in a receiver.2. The method of claim 1 , further comprising:collecting the tissue on the filter by aspirating fluid and cut tissue from an inlet port of the tissue collection device on the upstream side of the filter toward an outlet port on a downstream side of the filter prior to injecting the biocompatible gel.3. The method of claim 2 , further comprising:opening a receiver port of the tissue collection device after closing the inlet port, the receiver port located between the inlet port and the filter;wherein the combination is collected in the receiver via the receiver port.4. The method of claim 3 , further comprising:closing the inlet port after collecting the tissue on the filter and prior to injecting the biocompatible gel.5. The method of further comprising:coupling an introducer to the outlet port; andcoupling the receiver to the receiver port.6. The method of claim 5 , wherein the introducer comprises a first syringe.7. The method of claim 5 , wherein the receiver comprises container portion of second syringe.8. The method of claim 7 , wherein the receiver comprises a static mixer portion coupled between ...

ALLOGENEIC MICROVASCULAR TISSUE FOR SOFT TISSUE TREATMENTS

Disclosed are products and methods for treating soft tissue injuries. The provided methods include the production of processed or cryopreserved microvascular tissue. Also provided are products and methods of using processed or cryopreserved microvascular tissue for the treatment of soft tissue injuries. 1. A method for repair or regeneration of a tissue selected from the group consisting of tendon , ligament , and skin , said method comprising applying a plurality of uncultured allogeneic stem or progenitor cells to said tissue and thereby effecting repair or regeneration of the tissue as compared to a control tissue to which uncultured allogeneic stem or progenitor cells are not applied.2. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells are included in a processed or cryopreserved microvascular tissue.3. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells comprise xenogeneic cells.4. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells is less than 50% viable.5. The method of claim 1 , wherein said plurality of uncultured allogeneic stem or progenitor cells contains substantially no viable cells.6. A composition comprising a plurality of uncultured stem or progenitor cells formulated for implantation into an allogeneic or xenogeneic recipient claim 1 , said composition having tissue healing activity and comprising no bone or bone-derived matrix.7. The composition of claim 6 , wherein said plurality of uncultured allogeneic stem or progenitor cells are included in a processed or cryopreserved microvascular tissue.8. The composition of claim 6 , wherein said plurality of uncultured allogeneic stem or progenitor cells is less than 50% viable.9. The composition of claim 6 , wherein said plurality of uncultured stem or progenitor cells contains substantially no viable cells.10. The composition of claim 6 , wherein said composition is ...

SINGLE CELLS PLURIPOTENT STEM CELLS IN A SUSPENSION CULTURE

Provided is an isolated population of human pluripotent stem cells comprising at least 50% human pluripotent stem cells characterized by an OCT4+/TRA1-60−/TRA1-81−/SSEA1+/SSEA4− expression signature, and novel methods of generating and maintaining same in a pluripotent, undifferentiated state a suspension culture devoid of cell clumps. Also provided are novel culture media, cell cultures and methods for culturing pluripotent stem cells in a suspension culture or a two-dimensional culture system while maintaining the cells in a proliferative, pluripotent and undifferentiated state. The novel culture media comprise interleukin 11 (IL11) and Ciliary Neurotrophic Factor (CNTF); bFGF at a concentration of at least 50 ng/ml and an IL6RIL6 chimera; or an animal contaminant-free serum replacement and an IL6RIL6 chimera. Also provided are methods for generating lineage-specific cells from the pluripotent stem cells. 1. A method of generating a mesenchymal stem cell in a suspension culture , comprising culturing an isolated population of pluripotent stem cells in a suspension culture under conditions suitable for differentiation of pluripotent stem cells to mesenchymal stem cells , wherein said isolated population of pluripotent stem cells comprises at least 50% human pluripotent stem cells characterized by an OCT4/TRA1-60/TRA1-81/SSEA1/SSEA4expression signature and being capable of differentiating into endoderm , ectoderm and mesoderm embryonic germ layers , thereby generating the mesenchymal stem cell in the suspension culture.2. The method of claim 1 , wherein said conditions comprise culturing in a presence of a differentiation culture medium suitable for differentiation of said pluripotent stem cells to the mesenchymal stem cells.3. The method of claim 2 , wherein said culturing comprises a gradual transfer of the pluripotent stem cells from a culture medium supporting expansion of said pluripotent stem cells in an undifferentiation state into said differentiation ...

BROWN FAT CELL COMPOSITIONS AND METHODS

Methods of developing and using cell lines, such as stem cell lines, for therapeutic or cosmetic use. In one embodiment, the cell lines are used to treat a wide range of degenerative and metabolic disorders including, but not limited to, obesity, diabetes, hypertension, and cardiac deficiency. Also described are methods of using such cell lines to screen for compounds that play a role in regulating a variety of processes. 121-. (canceled)22. A method of generating a stem cell , the method comprising:isolating a stem cell from brown fat tissue;culturing the stem cell in a culture medium under a selective pressure of 0 to 5% oxygen, wherein the culture medium does not comprise a xenogenic animal product; andselecting viable stem cells capable of growth in culture medium under the selective pressure of 0 to 5% oxygen.23. The method of claim 22 , further comprising: providing the selected claim 22 , viable stem cells for implantation.24. The method of claim 22 , wherein the selective pressure is 1 to 5% oxygen.25. The method of claim 22 , wherein the brown fat tissue is an allogeneic source.26. The method of claim 22 , wherein the brown fat tissue is an autogeneic source.27. The method of claim 22 , wherein the selected claim 22 , viable stem cells are allogeneic stem cells.28. The method of claim 22 , wherein the selected claim 22 , viable stem cells are autogeneic stem cells.29. The method of claim 27 , wherein the allogeneic stem cells are positive for one or more of the following cell surface markers: CD90 claim 27 , HLA-ABC claim 27 , CD105 claim 27 , CD73 claim 27 , CD166 claim 27 , or CD44.30. The method of claim 27 , wherein the allogeneic stem cells are negative for one or more of the following cell surface markers: CD34 claim 27 , HLA-DR claim 27 , Lin claim 27 , or CD117.31. The method of claim 28 , wherein the autogeneic stem cells are positive for one or more of the following cell surface markers: CD90 claim 28 , HLA-ABC claim 28 , CD105 claim 28 , CD73 ...

Decellularized Adipose Tissue

This invention provides a method for decellularizing adipose tissue, comprising subjecting the adipose tissue to one or more incubations in an enzymatic digestion solution containing one or more enzymes, and one or more solvent extractions, wherein decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional structure is obtained. The invention also provides a decellularized adipose tissue comprising an extracellular matrix with well-preserved three-dimensional architecture, and bioscaffolds, microcarrier beads, and coatings comprising the decellularized adipose tissue.

POROUS CELL SCAFFOLD AND PRODUCTION METHOD THEREOF

For easily seeding cells in its scaffold, a porous cell scaffold is produced by steps of filling a guiding solution with kinematic viscosity being 50 to 450% of that of a culture medium, in a whole continuous small hole structure having hole diameters of 5 to 3200 μm and an average hole diameter of 50 to 1500 μm, of a sheet-shaped or block-shaped scaffold having a thickness of 2 mm or more, supplying thereafter a culture medium with cells being suspended to an upper side of the scaffold, sucking the guiding solution from a lower side of the scaffold by low suction force, and entering thereby the culture medium with cells being suspended into the whole small hole structure, where a water absorber such as a filter paper is preferably used for sucking the guiding solution by low suction force. 1. A production method of a porous cell scaffold comprising steps of:filling a guiding solution in a whole continuous small hole structure of a sheet-shaped or block-shaped scaffold having a continuous small hole structure with hole diameters of 5 to 3200 μm and an average hole diameter of 50 to 1500 μm, and having a thickness of 2 mm or more;supplying thereafter a culture medium with cells being suspended to an upper side of the scaffold;sucking the guiding solution from a lower side of the scaffold; andentering thereby the culture medium with cells being suspended into the whole small hole structure of the scaffold.2. The production method of a porous cell scaffold as claimed in claim 1 ,wherein kinematic viscosity at a time of use of the guiding solution is 50 to 450% of kinematic viscosity at a time of use of a culture medium.3. The production method of a porous cell scaffold as claimed in claim 1 ,wherein the guiding solution is water, physiological saline, a buffer solution, body fluid, or a culture medium.4. The production method of a porous cell scaffold as claimed in claim 1 ,wherein a means for sucking of the guiding solution from a lower side of the scaffold is a water ...

AGENT FOR INDUCING DIFFERENTIATION OF WHITE ADIPOCYTES INTO BROWN-LIKE ADIPOCYTES

This invention relates to an agent for inducing differentiation of white adipocytes into brown-like adipocytes comprising a compound which is a cyclization reaction product of a hydroxystilbene and which is represented by Formula (1): (wherein each of Rto Ris a hydrogen atom, a hydroxyl group, a saturated or unsaturated, straight or branched alkoxy group having 1 to 10 carbon atoms, or a saturated or unsaturated, straight or branched alkyl group having 1 to 10 carbon atoms, and Rto Rmay be same or different), or a pharmaceutically acceptable salt thereof. 2. The agent for inducing differentiation of white adipocytes into brown-like adipocytes according to wherein the hydroxystilbene is resveratrol.3. (canceled)5. The composition of the agent for inducing differentiation of white adipocytes into brown-like adipocytes according to wherein the phenol content in 20 mg/mL solid is 100 μg/mL or less.6. A food claim 4 , pharmaceutical agent claim 4 , and quasi drug comprising the agent for inducing differentiation of white adipocytes into brown-like adipocytes according to or .7. A food claim 4 , pharmaceutical agent claim 4 , and quasi drug comprising the composition of the agent for inducing differentiation of white adipocytes into brown-like adipocytes according to or .8. A method for producing the composition of the agent for inducing differentiation of white adipocytes into brown-like adipocytes according to or which comprises a step for removing phenol contained therein by one or more steps selected from the group consisting of Steps (a) to (c):(a) a step for allowing a solution obtained by heating resveratrol under an alkaline condition to be brought into contact with a solid adsorbent and recovering the adsorbed constituents;(b) a step for adjusting a solution obtained by heating resveratrol under an alkaline condition to pH7 or below to effect precipitation and recovering the precipitated material; and,(c) a step for heating a solution obtained by heating ...

METHOD FOR THE PRODUCTION OF CELLULAR PARTICULATE WITH ANTITUMOR ACTIVITY

Method for the production of cellular particulate with antitumor activity, which comprises isolating the cellular particulate originating from a cell population with a phenotype that can be attributed to human adipose tissue derived pericytes (AD-PC) that express antitumor TRAIL. 1. Method for the production of cellular particulate with antitumor activity , wherein it comprises isolating the cellular particulate from a supernatant collected from a cell population culture expressing an antitumor soluble TRAIL transfected with a retroviral vector which has a human adipose tissue derived pericytes (AD-PC) phenotype.2. Method as in claim 1 , wherein said cell population with a human adipose tissue derived pericytes (AD-PC) phenotype is transfected in a stable manner.3. Method as in claim 1 , wherein said cells with a pericytes (PC) phenotype are generated from tissues chosen from: adipose tissue claim 1 , osteo-medullary tissue claim 1 , placenta claim 1 , amniotic fluid claim 1 , dental pulp claim 1 , muscle tissue claim 1 , cardiac tissue claim 1 , umbilical cord claim 1 , cutaneous tissue claim 1 , pancreatic tissue claim 1 , intestinal tissue claim 1 , decidual endometrial tissue.4. Method as in claim 1 , wherein said population expressing TRAIL is selected from: autologous cells claim 1 , allogenic cells claim 1 , human cells claim 1 , animal cells.5. Cellular particulate claim 1 , wherein it comprises particles that have a closed circular membrane formed by a double layer consisting partially or entirely of phospholipids.6. Cellular particulate as in claim 5 , wherein said particles have a maximum size comprised between 40 nm and 5000 nm.7. Cellular particulate as in claim 6 , wherein said particles have a maximum size comprised between 500 nm and 3000 nm.8. Cellular particulate as in claim 5 , wherein said particles have TRAIL in their lumen with anti-cancer activity. The present invention concerns a method for the production of cellular particulate with ...

Apparatus and methods for cell isolation

A unitary apparatus for isolating cells from adipose tissue including a lipid separation processor with a dispersing head equipped with a plurality of ports and a digestion chamber for dissociation of the constituent cells disposed in adipose tissue. The lipid separating apparatus is useful for the separation of lipids and adipocytes from a mixed cell population. A cell seeding chamber may be attached to the cell isolation apparatus. The components of the apparatus may be packaged in modular kit form. 1. An apparatus for treating lipoaspirate obtained from adipose tissue , from which to recover a reparative cell population , the apparatus comprising filtration means for preliminary separation of regenerative cells from the lipoaspirate , and phase separation means for isolation of the reparative cells without centrifugation.2. An apparatus for isolating reparative cells from body tissue , comprising:a digestion chamber having at least one inlet port and at least one outlet port, said chamber adapted for digestion of body tissue during enzymatic dissociation of the body tissue into a dissociated cell mixture;a filter for receiving a fluid flow of enzymatically-dissociated body tissue from the digestion chamber, and for dispersing the filtered fluid flow in an emulsion consisting of a reparative cell population component and other tissue-derived matter component; anda fluid phase separation unit in fluid communication with the filter to receive said emulsion for fluid phase separation of the reparative cell population component from the other tissue-derived matter component according to differential specific gravity.3. The apparatus of claim 2 , including a port for introducing compounds into the fluid phase separation unit to facilitate separation of the reparative cell population component.4. The apparatus of claim 2 , including a container in fluid communication with the fluid phase separation unit for at least one of cell banking and cell culturing.5. The ...

COMPOSITIONS AND METHODS FOR IMPLANTATION OF PROCESSED ADIPOSE TISSUE AND PROCESSED ADIPOSE TISSUE PRODUCTS

The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue. 129.-. (canceled)30. An acellular delipidized biocompatible biomaterial comprising a mammalian adipose tissue extracellular matrix (ECM) derived from cadaveric adipose tissue , the biomaterial having between 1% to 0.001% adipose lipid by weight , wherein the biomaterial is non-inflammatory and substantially non-immunogenic when implanted.31. The biomaterial of claim 30 , wherein the adipose tissue is human adipose tissue or porcine adipose tissue.32. The biomaterial of claim 30 , wherein the composition comprises 0.2 μg/mg or less of DNA.33. The biomaterial of claim 30 , further comprising a cross-linking agent.34. The biomaterial of claim 33 , wherein the cross-linking agent is selected from the group consisting of carbodiimide (EDC) claim 33 , hexamethylene diisocyanate (HMDC) claim 33 , gluteraldehyde claim 33 , proanthocyanidin claim 33 , ribose claim 33 , threose claim 33 , and lysyl oxidase claim 33 , carbodiimide claim 33 , polyepoxy ethers claim 33 , divinyl sulfone (DVS) claim 33 , genipin claim 33 , polyaldehyde and diphenylphosphoryl azide (DPPA) claim 33 , genipin claim 33 , epoxy compounds claim 33 , dialdehyde starch claim 33 , glutaraldehyde claim 33 , formaldehyde claim 33 , dimethyl suberimidate claim 33 , carbodiimides claim 33 , succinimidyls claim 33 , diisocyanates claim 33 , and acyl azide.35. The biomaterial of claim 30 , wherein the biomaterial is injectable.36. The biomaterial of claim 30 , wherein the biomaterial is sterilized.37. A composition comprising at least one biomaterial of and at least one pharmaceutically acceptable carrier or adjuvant.38. A method for preparing processed adipose tissue claim 30 , the method comprising the steps of:a. providing mammalian tissue comprising solid adipose;b. isolating the adipose from the non-adipose material in the tissue; ...

METHOD FOR PRODUCING STEM CELL CULTURE PLATE AVAILABLE FOR TISSUE ENGINEERING USING 3D PRINTING FOR HUMAN ORGANOID GENERATION

A method for producing a cell culture plate for human organoid generation using 3D printing is proposed. The method includes the steps of: (a) feeding filament-shaped biodegradable polymer materials, which are not toxic to the human body, and a compatibilizer for improving interfacial adhesion between the polymer materials, into a 3D printer; and (b) producing a cell culture plate using the 3D printer. The cell culture plate is produced by feeding biodegradable polymer materials, which is a blended combination of PLA and PCL, and an appropriate compatibilizer, into a 3D printer. The produced cell culture plate is not toxic to the human body, can culture cells in a desired shape, and has excellent biocompatibility so that it can be applied directly in vivo without detaching cells from the plate. 1. A method for producing a cell culture plate for human organoid generation , the method comprising the steps of:(a) feeding filament-shaped biodegradable polymer materials, which are not toxic to the human body, and a compatibilizer for improving interfacial adhesion between the polymer materials, into a 3D printer; and(b) producing the cell culture plate using the 3D printer.2. The method of claim 1 , wherein the biodegradable polymers are selected from the group consisting of PCL (polycaprolactone) claim 1 , PLA (polylactic acid) claim 1 , PDO (polydioxanone) claim 1 , PGA (polyglycolide) claim 1 , PLGA (polyglycolactide) claim 1 , PEG (polyethylene glycol) claim 1 , MB (polyhydroxybutyrate) claim 1 , PHV (polyhydroxyvalerate) claim 1 , propylene fumarate claim 1 , copolymers thereof claim 1 , and combinations thereof.3. The method of claim 2 , wherein the biodegradable polymers are a combination of PLA and PCL.4. The method of claim 3 , wherein a weight ratio between the PLA and the PCL is 99:1 to 9:1.5. The method of claim 4 , wherein the weight ratio between the PLA and the PCL is 97:1 to 97:10.6. The method of claim 5 , wherein the weight ratio between the PLA and the ...

COMPOSITIONS AND METHODS FOR COLLECTING, WASHING, CRYOPRESERVING, RECOVERING AND RETURN OF LIPOASPIRATES TO PHYSICIAN FOR AUTOLOGOUS ADIPOSE TRANSFER PROCEDURES

The invention details a cryoprotectant and the methods to prepare biological tissue and related business methods and systems. The invention is directed to methods for collecting, washing, cyropreserving, recovering, and return of lipoaspirates to physicians for autologous adipose tissue transfer procedures in patients. In an embodiment, the invention is directed to a cryoprotectant solution for cryopreserving biological tissue essentially of a polyol and a crysalloid. 1. A cryoprotectant solution for cryopreserving biological tissue consisting essentially of:a. a polyol; andb. a crystalloid.2. The cryoprotectant solution of claim 1 , wherein the polyol is glycerol.3. The cryoprotectant solution of claim 2 , wherein the crystalloid is Lactated Ringers solution.4. The cryoprotectant solution of claim 3 , wherein the biological tissue is adipose tissue.5. The cryoprotectant solution of claim 4 , wherein the glycerol and Lactated Ringers are in a ratio of approximately 1 to 10 respectively.6. The cryoprotectant solution of claim 5 , wherein the solution establishes equilibration within 30 minutes after combination with adipose tissue.7. A system for cryopreserving biological tissue comprising:a. a cryoprotectant solution which does not cause leaching from a plastic based containers;b. a plastic based container;8. The system of claim 7 , wherein the cryoprotectant solution comprises (i) a polyol and (ii) and (ii) a crystalloid.9. The system of claim 8 , wherein the polyol is glycerol.10. The system of claim 9 , wherein the crystalloid is Lactated Ringers solution.11. The system of claim 10 , wherein the plastic based container comprises at least one Luer tube port and at least one spike port.]12. A method to obtain high percent viability of adipocytes after cryopreservation and thawing of adipose tissue comprising the steps of:a. obtaining an adipose tissue specimen;b. washing the adipose tissue with a wash solution comprising Lactated Ringer's solution;c. adding a ...

MULTIPOTENT STEM CELLS AND USES THEREOF

The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCF4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiating the stem cells, are also provided. 1. A method of enhancing recovery from joint surgery , comprising administering to the joint during surgery to repair the joint a composition comprising stem or progenitor cells that express a stem cell transcription factor but do not detectably express MHC Class I or cell surface markers CD13 , CD44 , CD45 , and CD90 in an amount effective to enhance recovery , and a pharmaceutically acceptable carrier.2. The method of claim 1 , wherein the stem cells are capable of proliferating and differentiating into ectoderm claim 1 , mesoderm and endoderm.3. The method of claim 1 , wherein the stem cells are synovial fluid derived claim 1 , blood derived or tissue derived.4. The method of claim 1 , wherein the stem cells are isolated from a mammal.5. The method of claim 4 , wherein the stem cell is isolated from a human.6. The method of claim 4 , wherein the stem cells are isolated from an adult mammal.7. The method of claim 1 , wherein the stem cells are autologous with respect to a recipient undergoing the joint surgery.8. The method of claim 1 , wherein the stem cells are allogeneic ...

Tissue scaffold

Tissue scaffold matrices, and methods of their use, are described. The matrices comprise an enzyme that is able to convert a substrate to release hydrogen peroxide and a substrate for the enzyme. The matrices may be impregnated with cells, such as stem cells. Also described are cell cultures, and methods for proliferating and/or differentiating cells.

Method and apparatus for increasing adipose vascular fraction

A method and device for processing mammalian adipose tissue such that the vascular rich fraction is separated from the vascular poor fraction, Mammalian adipose tissue in the form of morselated surgical biopsies and/or lipoaspirate from liposuction is placed within a novel syringe attached to a detection device measuring either color, light saturation, infra-red light, heme, iron or oxygen saturation. This process involves no label and minimal manipulation and handling of the tissue. This process and device may also be used intra-operatively under sterile conditions for immediate use within the same individual receiving liposuction or surgery.

USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN ADIPOCYTE DIFFERENTIATION PROCEDURE

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor. 1. A composition for inhibiting differentiation of mesenchymal stem cells into adipocytes comprising human small leucine-zipper proteins as a differentiation regulator.2. The composition according to claim 1 ,wherein the human small leucine-zipper protein is represented by an amino acid sequence set forth in SEQ ID NO: 1.3. A composition for preventing or treating diabetes comprising human small leucine-zipper proteins.4. The composition according to claim 3 ,wherein the human small leucine-zipper protein is represented by an amino acid sequence set forth in SEQ ID NO: 1.5. The composition according to claim 3 ,wherein the human small leucine-zipper protein is included as a natural or recombinant protein type or a transformed stem cell type that overexpresses the human small leucine-zipper protein.6. A composition for preventing or treating obesity comprising an inhibitor of human small leucine-zipper proteins.7. The composition according to claim 6 ,wherein the human small leucine-zipper protein is represented by an amino acid sequence set forth in SEQ ID NO: 1.8. The composition according to claim 6 ,wherein the human small leucine-zipper protein is included as a natural or recombinant protein type or a transformed stem cell type that overexpresses the human small leucine-zipper protein.9. A screening method of a medicine for preventing or treating diabetes claim 6 , comprising:bringing genes of human small leucine-zipper proteins in contact with a candidate material outside a human body; ...

METHODS OF DIFFERENTIATING PREADIPOCYTES AND USES THEREOF

Described herein are methods of transdifferentiating preadipocytes, populations of transdifferentiated preadipocytes, and methods of using the transdifferentiated preadipocytes. 1. A method of transdifferentiating a preadipocyte , the method comprising:overexpressing Oct4 in a preadipocyte;culturing cells overexpressing Oct4 until about 100% confluent;passaging the cells overexpressing Oct4 after reacting 100% confluency; andexpanding cells overexpressing Oct 4 on a feeder cell layer.2. The method of claim 1 , further comprising overexpressing Klf4 in the preadipocyte.3. The method of claim 2 , wherein Klf4 is simultaneously overexpressed with Oct4.4. The method of claim 1 , wherein overexpression of Oct4 occurs via transfection or transduction of the preadipocyte with an exogenous Oct4 gene.5. The method of claim 1 , wherein overexpression of Klf4 occurs via transfection or transduction of the preadipocyte with an exogenous Klf4.6. The method of claim 1 , further comprising overexpressing Sox2 in the preadipocyte.7. The method of claim 6 , wherein overexpression of Sox2 occurs via transfection or transduction of the preadipocyte with an exogenous Sox2.8. The method of claim 1 , further comprising overexpressing cMyc in the preadipocyte.9. The method of claim 9 , wherein cMyc is simultaneously overexpressed with Oct 4.10. The method of claim 1 , wherein the preadipocytes have been passaged 3 times or less prior to overexpression of Oct4 claim 1 , Klf4 claim 1 , Sox2 claim 1 , or cMyc.11. The method of claim 1 , wherein the cells overexpressing Oct4 are expanded on the feeder layer for about 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 or more days.12. The method of claim 1 , wherein the cells overexpressing Oct 4 are cultured without passaging for about 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , or 5 days prior to the steps of passaging and expanding.13. The method of claim 1 , further comprising the step of contacting the cells overexpressing ...

NON-NATURALLY OCCURING THREE-DIMENSIONAL (3D) BROWN ADIPOSE-DERIVED STEM CELL AGGREGATES, AND METHODS OF GENERATING AND USING THE SAME

The present application provides non-naturally occurring 3D brown adipose-derived stem cell (BADSC) aggregates, methods of making the 3D BADSC aggregates, and methods of using the 3D BADSC aggregates. 1. A non-naturally occurring three-dimensional brown adipose derived stem cell aggregate wherein the three-dimensional brown adipose derived stem cell aggregate comprises brown adipose-derived stem cells that express one or more brown adipocyte gene in the absence of differentiation medium.2. The non-naturally occurring three-dimensional brown adipose derived stem cell aggregate of claim 1 , wherein the one or more brown adipocyte gene is selected from a group consisting of PPARα claim 1 , PPARγ claim 1 , PGC1β claim 1 , PRDM16 claim 1 , CEBPD claim 1 , CEBPB claim 1 , CEBPA claim 1 , TFAM claim 1 , PGC1α claim 1 , and PGC1β.3. The non-naturally occurring three-dimensional brown adipose derived stem cell aggregate of claim 1 , wherein the aggregate forms in a non-adherent environment.4. The non-naturally occurring three-dimensional brown adipose derived stem cell aggregate of claim 1 , wherein aggregate produces extracellular biologics selected from a group consisting of exosomes claim 1 , microRNA claim 1 , cytokines claim 1 , proteins claim 1 , and adipokines.5. An encapsulation system comprising the non-naturally occurring three-dimensional brown adipose derived stem cell aggregate of .6. The encapsulation system of claim 5 , wherein the encapsulation system is selected from the group consisting of alginate microcapsules claim 5 , cellulose hydrogels claim 5 , red blood cells claim 5 , porous polymer membranes claim 5 , 3D biological scaffolds claim 5 , polymers claim 5 , PEG-based hydrogels claim 5 , non-hydrogel beads claim 5 , and matrigel.7. The encapsulation system of claim 5 , wherein the encapsulation system is an encapsulation medical device.8. A method of making a non-naturally occurring three-dimensional brown adipose derived stem cell aggregate claim 5 , ...

ADIPOSE TISSUE MATRICES

The present disclosure provides tissue products produced from adipose tissues, as well as methods for producing such tissue products. The tissue products can include acellular extracellular matrices. In addition, the present disclosure provides systems and methods for using such products. 1. A tissue product , comprising:a decellularized adipose extracellular tissue matrix, wherein the tissue matrix has been formed into a sponge, and wherein the tissue matrix is partially cross-linked to maintain a porous structure of the sponge.2. The product of claim 1 , wherein the tissue matrix has been processed to remove at least some lipids.3. The product of claim 1 , wherein the tissue matrix is freeze-dried.4. The product of claim 1 , wherein the tissue matrix maintains the porous structure when implanted in a body.5. The product of claim 1 , wherein the tissue matrix maintains the porous structure when contacted with an aqueous environment.6. The product of claim 1 , wherein the tissue matrix maintains the porous structure when compressed.7. The product of claim 1 , wherein the tissue matrix contains hyaluronic acid and chondroitin sulfate.8. A tissue product claim 1 , comprising:an adipose extracellular tissue matrix comprising particles of decellularized adipose tissue formed into a sponge, and wherein the tissue matrix is partially cross-linked to maintain a porous structure of the sponge.9. The product of claim 8 , wherein the particles of decellularized adipose tissue are produced by cutting claim 8 , grinding claim 8 , or blending adipose tissue.10. The product of claim 8 , wherein the particles of decellularized adipose tissue are freeze-dried.11. The product of claim 8 , wherein the tissue matrix maintains the porous structure when implanted in a body.12. The product of claim 8 , wherein the tissue matrix maintains the porous structure when contacted with an aqueous environment.13. The product of claim 8 , wherein the tissue matrix maintains the porous structure ...

Biological Scaffolds, Products Containing Biological Scaffolds and Methods of Using the Same

The present disclosure provides biological scaffolds, methods for their synthesis and methods for their use. The biological scaffolds contain at least to components, the first, a mammalian cell platelet lysate and an adipose tissue-derived cell fraction (ATDCF) cell. Products that comprise the biological scaffold(s) may be a gel, a semi-solid or a solid substrate upon which at least one surface of the substrate is contacted with the biological scaffold to form a biocompatible material. The biological scaffold and biological scaffold containing products, can find utility in a vast range of medical device technologies and may be used for therapeutic purposes or for performing experimentation to test various pharmacological agents in vitro and in vivo. 1. A biological scaffold comprising a mammalian platelet lysate and an adipose tissue derived cellular fraction (ATDCF) cell.2. The biological scaffold of claim 1 , wherein the ATDCF cell comprises: a stromal vascular fraction cell claim 1 , an adipose-derived stromal cell claim 1 , an adipose derived stem cell claim 1 , a bone marrow-derived mesenchymal stromal cell and a bone marrow-derived mesenchymal stem cell.3. The biological scaffold of claim 2 , wherein the SVF cells are derived from human adipose tissue.4. The biological scaffold of claim 1 , wherein the mammalian platelet lysate is derived from human platelets.5. The biological scaffold of any one of claim 1 , wherein the biological scaffold comprises SVF cells.6. The biological scaffold of any one of claim 1 , wherein the biological scaffold comprises at least one of adipose-derived stromal cells and adipose-derived stem cells.7. The biological scaffold of any one of claim 1 , wherein the biological scaffold comprises at least one of bone marrow-derived mesenchymal stromal cells and bone marrow-derived mesenchymal stem cells.8. A therapeutic product comprising a biological scaffold and a substrate wherein the substrate has at least one surface for application ...

METHOD FOR THE IN VITRO OR EX VIVO AMPLIFICATION OF HUMAN ADIPOSE TISSUE STEM CELLS

The method for tin vitro or ex vivo amplification of human adipose tissue stem cells includes: —extracting a stromal vascular fraction of a human adipose tissue including endothelial cells of the human adipose tissue vascular network and human adipose tissue stem cells, and an extracellular matrix of the human adipose tissue, the extracellular matrix including endothelial cells of the human adipose tissue vascular network, human adipose tissue stem cells and collagen; —mixing the stromal vascular fraction and the extracellular matrix; and—culturing the mixture obtained in the preceding step, in suspension, in a culture medium. 1. A method for the in vitro or ex vivo amplification of human adipose tissue stem cells , comprising:extracting a stromal vascular fraction of a human adipose tissue comprising endothelial cells of the human adipose tissue vascular network and human adipose tissue stem cells, and an extracellular matrix of the human adipose tissue, the extracellular matrix comprising endothelial cells of the human adipose tissue vascular network, human adipose tissue stem cells and collagen;mixing the stromal vascular fraction and the extracellular matrix; andculturing the mixture obtained from the mixing, in suspension, in a culture medium.2. A method for the in vitro or ex vivo amplification of differentiated cells , comprising:extracting a stromal vascular fraction of a human adipose tissue comprising endothelial cells of the human adipose tissue vascular network and human adipose tissue stem cells, and an extracellular matrix of the human adipose tissue, the extracellular matrix comprising endothelial cells of the human adipose tissue vascular network, human adipose tissue stem cells and collagen;mixing the stromal vascular fraction and the extracellular matrix;culturing the mixture obtained from the mixing, in suspension, in a culture medium; andinducing a differentiation of the adipose tissue stem cells to obtain differentiated cells.3. The method ...

TISSUE PROCESSING APPARATUS AND METHOD FOR PROCESSING ADIPOSE TISSUE

A method for processing biological material containing stringy tissue in a container having a tissue collector disposed in a tissue retention volume on one side of an internal filter includes washing biological material contained in the tissue retention volume with wash liquid to the tissue retention volume and allowing the wash liquid and rotating the tissue collector disposed in the tissue retention volume relative to the container in a first direction of rotation about an axis of rotation to sweep the teeth positioned on the tissue collector through the biological material and to collect stringy material on the tissue collector. 166-. (canceled)67. An apparatus for processing biological material , the apparatus comprising:a container having an internal containment volume, the internal containment volume including a tissue retention volume and a filtrate volume;a filter disposed within the internal containment volume with the tissue retention volume on one side of the filter and the filtrate volume on another side of the filter and with the tissue retention volume and with the filtrate volume being in fluid communication through the filter;an inlet port in fluid communication with the tissue retention volume and configured to access the tissue retention volume for introducing human biological material into the tissue retention volume; and a tissue collector attached to the shaft, the tissue collector including multiple teeth positioned on the tissue collector; and', 'one or more mixing propellers attached to the shaft and being configured to direct flow toward the tissue collector., 'a rotatable shaft extending into the tissue retention volume and including68. The apparatus according to claim 67 , wherein the teeth positioned on the tissue collector include at least five teeth.69. The apparatus according to claim 67 , wherein each of the teeth has a height of from 1 millimeter to 10 millimeters.70. The apparatus according to claim 67 , wherein the mixing ...

MULTIPOTENT STEM CELLS AND USES THEREOF

The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CF34, CF49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiated stem cells, are also provided. 118-. (canceled)19. A master cell bank comprising a plurality of cryopreserved individually packaged populations of isolated adult stem cells , each population including at least 1×10or more adult stem cells , wherein said adult stem cells are capable of proliferating and differentiating into at least two of ectoderm , mesoderm , or endoderm , express at least one of Oct-4 , KLF-4 , Nanog , Sox-2 , Rex-1 , GDF-3 , and Stella and do not detectably express MHC Class I , CD90 , CD34 , CD44 , CD45 , or CD49.20. A method of forming an adipocyte , the method comprising culturing an adult stem cell under adipocyte-differentiating conditions , wherein said adult stem cell is capable of proliferating and differentiating into at least two of ectoderm , mesoderm , or endoderm , expresses at least one of Oct-4 , KLF-4 , Nanog , Sox-2 , Rex-1 , GDF-3 , and Stella and does not detectably express MHC Class I , CD90 , CD34 , CD44 , CD45 , or CD49.21. The method of claim 20 , wherein said adipocyte-differentiating conditions include culturing with at least one of dexamethasone claim 20 , 3-isobutyl- ...

FAT FRAGMENTATION DEVICE AND METHOD

The present invention provides a device for adipose tissue processing, microfragmentation and facilitation of mechanical separation of adipose derived stem cells (“ADSCs”), methods of using the device to generate a stromal vascular fraction (“SVF”) and methods of the SVF.

DIFFERENTIATION INDUCER TO BROWN-LIKE ADIPOCYTE OF WHITE ADIPOCYTE

To provide a differentiation inducer to brown-like adipocytes of white adipocytes containing a novel compound having an excellent differentiation induction action to brown-like adipocytes of white adipocytes as compared with resveratrol. 1a compound represented by Formula (1) or a pharmacologically permissible salt thereof:. A differentiation inducer to brown-like adipocytes of white adipocytes which is a reaction product of hydroxystilbenes and sinapic acid, comprising:wherein, in Formula (1), Rto Rrepresents a hydrogen atom, a hydroxy group, a saturated or unsaturated, linear or branched alkoxy group having 1 to 10 carbon atoms, or a saturated or unsaturated, linear or branched alkyl group having 1 to 10 carbon atoms and Rto Reach may be the same or different. 1. Field of the InventionThe present invention relates to a differentiation inducer to brown-like adipocytes of white adipocytes, the differentiation inducer which contains a reaction product of hydroxystilbenes and sinapic acid obtained by a synthesis method which is a very simple method and is applicable also to foods.2. Description of the Background ArtAdipocytes constituting the adipose tissue of mammals include two kinds of adipocytes, white adipocytes and brown adipocytes. The white adipocytes mainly have a role of accumulating the chemical energy taken in the form of triglyceride. On the other hand, the brown adipocytes have a role of converting the accumulated energy to heat. The brown adipocytes generate from myoblasts and are colored brown due to a large number of mitochondria contained in the cells. The brown adipocytes generate heat by the action of Uncoupling protein 1 (UCP1) expressed in the mitochondria (Non-patent Literature 1).A large amount of the brown adipose tissue constituted by the brown adipocytes can be seen in human infant, but the presence of brown fat in the tissue decreases with growth. It has been considered that since the derived stem cells are different, the brown adipocytes ...

MULTIPOTENT STEM CELLS AND USES THEREOF

The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCF4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiating the stem cells, are also provided. 1. A method of isolating a population of MHC class Istem cells from synovial fluid , said method comprising the steps: (a) providing synovial fluid from a subject; (b) enriching for a population of cells that are about 6 μm to 20 μm in size; and (c) depleting from said population cells expressing a stem cell surface marker and cells expressing an MHC class I protein , thereby isolating a population of MHC class Istem cells from synovial fluid.2. The method of claim 1 , further comprising testing the isolated population of MHC Class Istem cells for the expression of one or more cell surface markers selected from the group consisting of CD13 claim 1 , CD44 claim 1 , CD45 claim 1 , CD90 and CD105.3. The method of claim 2 , further comprising testing the isolated population of MHC Class Istem cells for the expression of one or more cell surface markers selected from the group consisting of MHC class II claim 2 , CD34 claim 2 , CD49c and CD73.4. The method of claim 1 , further comprising testing the isolated population of MHC Class Istem cells for the expression of one or more stem ...

Multipotent stem cells and uses thereof

The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCR4, CD133 or an SSEA. The invention further provides a proliferative stem cell, which expresses genes including Oct-4, Nanog, Sox2, GDF3, P16INK4, BMI, Notch, HDAC4, TERT, Rex-1, TWIST, KLF-4 and Stella but does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, CD73, CD105, CD90, CD66A, CD66E, CXCF4, CD133 or an SSEA. The cells of the invention can be isolated from adult mammals, have embryonic cell characteristics, and can form embryoid bodies. Methods for obtaining the stem cells, as well as methods of treating diseases and differentiating the stem cells, are also provided.

USE OF HUMAN SMALL LEUCINE ZIPPER PROTEIN IN ADIPOCYTE DIFFERENTIATION PROCEDURE

The present invention relates to a use of a human small leucine zipper protein in the adipocyte differentiation procedure. More specifically, sLZIP binds with PPARγ2 to induce the formation of a complex of HDAC3 and PPARγ2, thereby functioning as a corepressor to negatively inhibit the transcriptional activity of PPARγ2 and suppress the differentiation to adipocytes, and thus can be used as a marker for treating diabetes and obesity and developing new medicines therefor. 1. A screening method of a medicine for preventing or treating obesity , comprising:contacting a cell transformed with human small leucine-zipper proteins (sLZIP) and Peroxisome proliferator-activated receptor γ2 (PPARγ2) with a candidate material, wherein either the human sLZIP or PPARγ2 is coupled to a detectable component; anddetecting an increase in formation of the complex of the human small leucine-zipper proteins sLZIP and PPARγ2 in the cell, whereby said candidate material is determined to be a material capable of preventing or treating obesity.2. The screening method of claim 1 , wherein the cell is an animal cell.3. The screening method of claim 1 , wherein the detectable component is selected from the group consisting of a fluorescent protein claim 1 , Glutathione S transferase (GST) claim 1 , Flag-tag claim 1 , Myc-tag and HA-tag.4. The screening method of claim 1 , wherein detecting is carried out by a reaction using the detectable component claim 1 , or the human sLZIP or PPARγ2-specific antibody. This application is a divisional application of U.S. application Ser. No. 14/888,343, filed Oct. 30, 2015, which is the U.S. National Phase of International Application No. PCT/KR2014/003864, filed Apr. 30, 2014, which claims priority to Korea Application No. 10-2013-0048133, filed Apr. 30, 2013, the disclosures of which are incorporated herein by reference.The present invention relates to a use of human small leucine-zipper proteins in differentiation of mesenchymal stem cells into ...

Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair

Methods and compositions for directing adipose-derived stromal cells cultivated in vitro to differentiate into cells of the chondrocyte lineage are disclosed. The invention further provides a variety of chondroinductive agents which can be used singly or in combination with other nutrient components to induce chondrogenesis in adipose-derived stromal cells either in cultivating monolayers or in a biocompatible lattice or matrix in a three-dimensional configuration. Use of the differentiated chondrocytes for the therapeutic treatment of a number of human conditions and diseases including repair of cartilage in vivo is disclosed.

HUMAN ADIPOSE TISSUE PROGENITORS FOR AUTOLOGOUS CELL THERAPY FOR LIPODYSTROPHY

Methods for preparation of human adipose stem cells, enriched populations thereof, and white adipose cells derived therefrom, for treatment of lipodystrophy. 1. A method of providing a population of adipose progenitor cells for treating a subject with lipodystrophy associated with a genetic mutation , the method comprising: (i) culturing the primary adipose tissue in a protein-gel matrix in the presence of pro-angiogenic factors to induce the growth of a second population of cells;', '(ii) isolating cells from the second population to form a third population of cells comprising an enriched population of adipose progenitor cells; and, 'obtaining primary adipose tissue from a subject who has a lipodystrophy associated with a genetic mutation comprising a first population of adipose cells, and'}maintaining the population of adipose progenitor cells under conditions and for a time sufficient for proliferation of the cells,thereby providing a population of adipose progenitor cells for treating a subject with lipodystrophy associated with a genetic mutation.2. The method of claim 1 , wherein the second population of cells is subjected to enzyme digestion to produce the third population of cells.3. The method of claim 2 , wherein the second population of cells is subjected to dispase digestion.4. The method of claim 1 , further comprising mixing the genetically modified adipose progenitor cells with an injectable hydrogel.5. The method of claim 1 , wherein isolating cells from the second population comprises isolating CD45−CD29+CD34+CD24+CD144− cells from the second population.6. An isolated claim 1 , enriched population of adipose progenitor cells made by the method of .7. The isolated claim 6 , enriched population of adipose progenitor cells of claim 6 , which is in an injectable hydrogel.8. The method of claim 1 , further comprising genetically modifying the second population of cells or the third population of cells to correct the genetic mutation claim 1 , to provide ...

APPARATUSES, SYSTEMS, AND METHODS FOR CULTURING CELLS

Apparatuses, systems, and methods are provided for culturing a buoyant target tissue. Embodiments include a first surface configured to culture a first layer of supporting cells, and a second surface configured to culture a second layer of supporting cells. The first layer of supporting cells may be formed on a portion of the first surface and the second layer of supporting cells may be formed on a portion of the second surface. The buoyant target tissue may be added to the first layer of supporting cells. The second layer of supporting cells may be placed on the first layer of supporting cells such that the buoyant target tissue is sandwiched between the first layer of supporting cells and second layer of supporting cells. 1. A cell culture apparatus for culturing a buoyant target tissue , comprising:a first surface configured to culture a first layer of supporting cells; anda second surface configured to culture a second layer of supporting cells,wherein the first layer of supporting cells is formed on a portion of the first surface and the second layer of supporting cells is formed on a portion of the second surface, wherein the buoyant target tissue is added to the first layer of supporting cells, and the second layer of supporting cells is placed on the first layer of supporting cells such that the buoyant target tissue is sandwiched between the first layer of supporting cells and second layer of supporting cells.2. The apparatus of claim 1 , wherein the target tissue includes a buoyant cell type.3. The apparatus of claim 2 , wherein the target tissue is derived from at least one of a eukaryote claim 2 , a prokaryote claim 2 , a mammal claim 2 , a human claim 2 , a rodent claim 2 , a yeast claim 2 , a bacteria claim 2 , a plant claim 2 , and a fungi.4. The apparatus of claim 3 , wherein the target tissue is derived from a human.5. The apparatus of claim 4 , wherein the human target tissue includes white adipocytes claim 4 , individually isolated adipocytes ...

CELL CONSTRUCT AND CELL CONSTRUCT PRODUCTION METHOD

Disclosed is a cell structure comprising: a fragmented extracellular matrix component; and cells, wherein the cell structure comprises an intercellular vascular network, and the cells comprise at least adipocytes and vascular endothelial cells. 1. A cell structure comprising: a fragmented extracellular matrix component; and cells , whereinthe cell structure comprises an intercellular vascular network, andthe cells comprise at least adipocytes and vascular endothelial cells.2. The cell structure according to claim 1 , wherein the vascular network is formed among the adipocytes.3. The cell structure according to or claim 1 , wherein the adipocytes comprise mature adipocytes.4. The cell structure according to any one of to claim 1 , wherein an average length of the fragmented extracellular matrix component is 100 nm or more and 400 μm or less.5. The cell structure according to any one of to claim 1 , wherein a content of the extracellular matrix component in the cell structure is 0.01 to 90% by mass based on a dry mass of the cell structure.6. The cell structure according to any one of to claim 1 , wherein the fragmented extracellular matrix component comprises collagen.7. The cell structure according to any one of to claim 1 , further comprising fibrin.8. The cell structure according to any one of to claim 1 , for transplantation.9. A method for producing a cell structure comprising an intercellular vascular network claim 1 , the method comprising:a contacting step of bringing a fragmented extracellular matrix component and cells into contact with each other, wherein the cells (i) comprise at least adipocytes, stem cells, and vascular endothelial cells, or (ii) comprise at least adipose stem cells and vascular endothelial cells; anda culturing step of culturing the cells that are in contact with a fragmented extracellular matrix.10. The method according to claim 9 , wherein the cells comprise adipocytes claim 9 , adipose stem cells claim 9 , and vascular endothelial ...

REPROSOMES, AS EXOSOMES CAPABLE OF INDUCING REPROGRAMMING OF CELLS AND PREPARATION METHOD THEREOF

The present disclosure provides a reprosome that can induce reprogramming of a cell, in which the reprosome is characterized by including RNA of a gene involved in chromatin remodeling, in which the gene includes a kinase gene on a mitogen-activated protein kinase (MAPK) signal transduction system, and a gene having histone modification activity. The reprosome may be obtained from a stem cell difficult to process and/or from a readily obtainable somatic cell via a simple process including ultrasonic treatment. A reprogramming of one kind of a cell into another kind of a cell with a desired function can be achieved at a high efficiency in a short time via a simple treatment including a co-culturing between the reprosome and the cell. The cell thus obtained has the desired function without introduction of a chemical or foreign transcription factor into a genome and thus is more suitable for cell replacement therapies. Further, the present disclosure provides a composition including the reprosome and a method for regenerating a tissue by treating a body site with the composition to promote reprogramming of a cell present in the treated body site to a target cell having a desired function. 1. A reprosome capable of inducing cell reprogramming , wherein the reprosome comprises RNA of a gene involved in chromatin remodeling , wherein the gene includes a kinase gene on a mitogen-activated protein kinase (MAPK) signal transduction system , and a gene having histone modification activity.2. The reprosome of claim 1 , wherein the kinase gene is at least one selected from the group consisting of BRAF claim 1 , MAP2K3 claim 1 , MAP3K10 claim 1 , MAP3K4 claim 1 , MAP3K5 claim 1 , MAP3K7 claim 1 , MAPK12 claim 1 , RPS6KA4(MSK2) claim 1 , TAOK1 and TAOK2.3. The reprosome of claim 1 , wherein the gene having the histone modification activity is at least one selected from the group consisting of ASH1L claim 1 , CREBBP claim 1 , DOT1L claim 1 , EP300 claim 1 , GTF3C1 claim 1 , KAT2A ...

CONTROLLED OUTGASSING OF HYBERBARICALLY LOADED MATERIALS FOR THE DELIVERY OF OXYGEN AND OTHER THERAPEUTIC GASES IN BIOMEDICAL APPLICATIONS

Devices and methods for delivering oxygen and other therapeutic gases to a target, such as a tissue, a tissue-engineered construct, and a wound, in a controlled and sustained manner are disclosed. 1. A microtank for delivering one or more gases in a controlled and sustained manner , the microtank comprising one or more vessels , wherein the one or more vessels have a volume defined by at least one gas barrier and/or a means for mechanical support/confinement , wherein the volume of the one or more vessels is capable of being loaded with one or more gases at an atmospheric or a hyperbaric pressure and subsequently releasing the one or more gases in a controlled and sustained manner.2. The microtank of claim 1 , wherein the gas barrier and/or means for mechanical support/confinement comprises a material selected from the group consisting of polyvinyl alcohol (PVOH) claim 1 , ethylene vinyl alcohol (EVOH) claim 1 , polyethylene terephthalate (PET) claim 1 , polycaprolactone (PCL) claim 1 , poly(lactic-co-glycolic acid) (PLGA) claim 1 , poly(lactic acid) (PLA) claim 1 , poly(glycolic acid) (PGA) claim 1 , a biocompatible polymer claim 1 , a silica coating claim 1 , a metal coating claim 1 , a ceramic claim 1 , and combinations thereof.3. The microtank of claim 1 , wherein the one or more vessels have a dimension ranging from about 1 nanometer to about 1000 micrometers.4. The microtank of claim 3 , wherein the one or more vessels have a dimension ranging from about 1 micrometer to about 1000 micrometers.5. The microtank of claim 1 , further comprising one or more gases loaded in the volume of the one or more vessels under pressure in a hyperbaric environment.6. The microtank of claim 5 , further comprising one or more gases loaded in the volume of the one or more vessels at a temperature having a range from below 0° C. up to a limiting combustion temperature of the one or more gases or a material comprising the microtank.7. The microtank of claim 6 , further comprising ...

SYSTEMS AND METHODS FOR MEDICAL DEVICE CONTROL

Systems, devices, and methods of the present disclosure assist with management of tubes and hoses during surgical procedures. The systems, devices, and methods provide for the proper opening and closing of tubes to facilitate performance of steps in a surgical procedure. Systems, devices, and methods of the present disclosure control fluid delivery to and from a medical device, including devices for tissue processing and cleaning. 1. A tissue treatment system , comprising: an exterior wall surrounding an interior volume for holding tissue; and', 'a filter structure for processing tissue; and, 'a container, including a first plate having a plurality of first openings passing therethrough;', 'a second plate having a plurality of second openings passing therethrough; and', 'a third plate having one or more third openings passing therethrough;', 'wherein the first plate, second plate, and third plate are operably connected and wherein setting the third plate in a first position places a first subset of the plurality of first openings in fluid communication with a first subset of the plurality of second opening, setting the third plate in a second position places a second subset of the plurality of first openings in fluid communication with a second subset of the plurality of second openings, and setting the third plate to a third position places a third subset of the plurality of first openings in fluid communication with a third subset of the plurality of second openings., 'a flow management device, including2. The tissue treatment system of claim 1 , further comprising a rotatable connection to operably connect the first plate claim 1 , the second plate claim 1 , and the third plate.3. The tissue treatment system of claim 1 , further comprising a plurality of seals to prevent material from passing between the first plate and the third plate or the second plate and the third plate.4. The tissue treatment system of claim 3 , wherein at least one of the first plate claim ...

PRODUCTION OF BROWN ADIPOCYTES

Use of a transforming growth factor beta (TGF-β) signalling inhibitor for producing a population of brown adipocytes in vitro. 17-. (canceled)8. A method for producing a population of brown adipocytes comprising the step of contacting a population of cells with a transforming growth factor beta (TGF-β) inhibitor.9. The method of claim 8 , wherein the TGF-β inhibitor is a SMAD2 and SMAD3 inhibitor and/or an activin inhibitor.11. The method of claim 8 , wherein the population of cells contacted with the TGF-β inhibitor is a population of mesoderm cells.12. The method of claim 8 , wherein the population of cells contacted with the TGF-β inhibitor is a population of cells that express FOXC1 claim 8 , FOXC2 claim 8 , MRF4 claim 8 , MSGN1 claim 8 , MYF5 claim 8 , PAX3 claim 8 , PAX7 claim 8 , PRRX1 claim 8 , SIX1 and/or TBX6.13. The method of claim 8 , wherein the population of cells contacted with the TGF-β inhibitor is produced from a population of stem cells.14. The method of claim 8 , wherein the method comprises the steps:culturing a population of mesoderm cells for about 1-15 days, in the presence of the TGF-β inhibitor; andculturing the population of cells provided by step (a) for about 20-50 days.15. The method of claim 14 , wherein the cultures of steps (a) and (b) are adherent cultures.16. The method of or claim 14 , wherein the method comprises the further step of:culturing the population of cells provided by step (b) under conditions suitable for the formation of aggregated brown adipocytes.17. (canceled)18. A population of brown adipocytes obtainable in vitro using a transforming growth factor beta (TGF-β) inhibitor.19. (canceled)20. A method for use in surgery or as a therapy comprising administering to an individual in need of same a population of brown adipocytes claim 14 , wherein the population of brown adipocytes is produced by a method of contacting a population of cells with a transforming growth factor beta (TGF-β) inhibitor.21. The population of ...

Systems and methods for the digestion of adipose tissue samples obtained from a client for cryopreservation

The present invention is directed to systems and methods of processing aspirated adipose tissue for the isolation of stromal vascular fraction derived stem cells.

TISSUE PROCESSING DEVICE AND ASSOCIATED SYSTEMS AND METHODS

Tissue processing devices are provided. The tissue processing devices can be used to process and transport tissue in a closed and continuous environment. The devices can be used for adipose tissue transfer, including autologous fat grafting. 1. A tissue processing device , comprising:a body including a cavity formed therein, the cavity comprising a first cylindrical compartment and a second compartment, and the body defining a proximal section and a distal section;a tissue collection port formed in a wall of the body proximal section and adapted to receive tissue therethrough and in fluid communication with the cavity;at least one injection port formed in fluid communication with the cavity;a rotary transfer device comprising a helical blade and at least one catcher extending from a rotatable shaft of the rotary transfer device;an automated actuation unit for rotatably driving the rotary transfer device;a filter separating the first cylindrical compartment from the second compartment, wherein the filter defines at least a portion of a wall surrounding the rotary transfer device; andan extrusion port formed in a wall of the body distal section and adapted for removal therethrough of the tissue from the cavity.2. The tissue processing device of claim 1 , wherein the tissue collection port and the extrusion port are in fluid communication with the first cylindrical compartment.3. The tissue processing device of claim 1 , wherein the helical blade is disposed within the first cylindrical compartment for transferring the tissue from the body proximal section to the body distal section.4. The tissue processing device of claim 1 , wherein the at least one injection port comprises:a first injection port formed in the wall of the body proximal section; andsecond and third injection ports formed in a wall of the body distal section.5. The tissue processing device of claim 4 , wherein the first claim 4 , second claim 4 , and third injection ports are in fluid communication ...

USE OF MESOTHELIAL CELLS IN TISSUE BIOENGINEERING AND ARTIFICIAL TISSUES

Use of mesothelial cells and artificial tissues comprising mesothelial cells in regenerative medicine, wherein the mesothelial cells have been cultivated in a Mesothelial Retaining Phenotype Media (MRPM) containing a glucocorticoid, Culture media, pharmaceutical compositions and uses thereof. 1. A composition comprising mesothelial cells for use in the treatment of a diseased or damaged tissue or organ.2. The composition for use according to claim 1 , wherein the mesothelial cells are autologous adipose tissue mesothelial cells (ATMCs).3. The composition for use according to any one of - claim 1 , wherein the mesothelial cells are cultivated in a suitable medium further comprising a glucocorticoid4. The composition for use according to any one of - claim 1 , wherein the mesothelial cells are cultivated in Mesothelial Retaining Phenotype Media (MRPM) comprising a glucocorticoid wherein said Mesothelial Retaining Phenotype Media (MRPM) consists of a DMEM low glucose media supplemented with a low concentration (2%) of inactivated fetal bovine serum claim 1 , 1% B27 supplements claim 1 , 1% penicillin-streptomycin and 100 μM of the anti oxidant β-mercaptoethanol.5. The composition for use according to or claim 1 , wherein the glucocorticoid is hydrocortisone at a concentration of 0.1 to 100 μg/ml.6. The composition for use according to any one of - claim 1 , wherein the diseased or damaged tissue is the endothelium.7. The composition for use according to claim 6 , wherein the diseased or damaged tissue is selected from the endothelium that lines the interior surface of blood vessels and lymphatic vessels claim 6 , or the corneal endothelium.8. The composition for use according to any one of - claim 6 , wherein the diseased or damaged tissue is a serous membrane.9. An in vitro method for preparing an artificial tissue comprising;a. sedding a support material with isolated mesothelial cells, andb. Culturing the isolated mesothelial cells in the support material of (a) in ...

Microfluidic platform for target and biomarker discovery for non-alcoholic fatty liver disease

A method for developing stratified medicine for nonalcoholic fatty liver disease (NAFLD includes obtaining a microphysiological system (MPS) comprising a liver tissue cytoarchitecture, adipose tissue, or both. The method includes inducing metabolic dysfunction representing NAFLD in the liver or adipose tissue of the MPS. The method includes generating, based on inducing the metabolic dysfunction, transcriptomics data for the MPS. The method includes applying a drug to the MPS using a dosing regimen. The method includes monitoring changes in the transcriptomics data based on applying the drug. The method includes generating a model relating the changes in the transcriptomics data to the dosing regimen of the drug.

PROCESS AND COMPOSITIONS FOR ACHIEVING MAMMALIAN ENERGY BALANCE

Disclosed is a method of achieving optimal mammalian energy balance using forskolin on a particular physiological and developmental stage of the mammalian cellular system. 1. A method of achieving mammalian energy balance using forskolin in a process of adipogenesis inhibition wherein forskolin is added separately to pre-adipocytes before differentiation and also to mature adipocytes to comparatively evaluate adipogenesis inhibition potential , said process comprising steps of:{'sup': '4', 'a) Seeding mammalian adipocyte precursor cells (pre-adipocytes) in wells of microplates wherein approximately 60×10cells are seeded for 48-72 hours to get 70-80% confluence;'}b) Adding forskolin at concentrations of 50 μg/ml and 100 μg/ml in the pre-seeded microplates of step a consisting of undifferentiated pre-adipocytes;c) Adding 200 μl of freshly prepared Adipogenesis induction medium to the wells;d) Adding 200 μl of freshly prepared Adipogenesis progression medium after 72 hours of incubation with the Adipogenesis induction medium in step c;e) Incubating the cells treated with forskolin (step b), adipogenesis induction medium (step c) and adipogenesis progression medium (step d) for 48 hours in a humidified atmosphere (37 deg. C.) of 5% CO2 and 95% air;f) Fixing the cells of step e by adding 100 μl of 10% formalin and staining using the Oil Red O technique;g) Reading the optical density of cells of step f at 492 nm in a microplate reader and expressing the results as inhibitory concentration (IC50) values using the graph pad prism software;h) Calculating the percentage inhibition of adipogenesis in the cells of steps f and g using the formula, C-T/T×100, wherein C is the absorbance of Oil Red O in differentiating/undifferentiated cells and T is the absorbance of Oil Red O in sample treated differentiating/undifferentiated cells.i) Adding 200 μl of freshly prepared Adipogenesis induction medium to the wells of step a.j) Adding 200 μl of freshly prepared Adipogenesis ...

COMPOSITIONS AND METHODS FOR IMPLANTATION OF PROCESSED ADIPOSE TISSUE AND PROCESSED ADIPOSE TISSUE PRODUCTS

The invention provides compositions and methods for the preparation of processed adipose tissue. The invention further provides methods of use of the processed adipose tissue. 1. An acellular delipidized biocompatible biomaterial comprising a mammalian adipose tissue extracellular matrix (ECM) having between about 1% to about 0.001% adipose lipid by weight , and is thereby non-inflammatory when implanted.2. The acellular adipose biocompatible biomaterial composition of claim 1 , wherein the composition further comprises at least one material from the group consisting of: anesthetic claim 1 , analgesic claim 1 , antibiotic claim 1 , antimicrobial claim 1 , growth factors claim 1 , cryopreservative claim 1 , antioxidant claim 1 , free radical scavenger claim 1 , caspase inhibitor claim 1 , vitamin claim 1 , and a cell.3. The acellular adipose biocompatible biomaterial composition of claim 1 , further comprising a cross-linking agent.4. The composition of claim 3 , wherein the cross-linking agent is selected from the group consisting of carbodiimide (EDC) claim 3 , hexamethylene diisocyanate (HMDC) claim 3 , gluteraldehyde claim 3 , proanthocyanidin claim 3 , ribose claim 3 , threose claim 3 , and lysyl oxidase claim 3 , carbodiimide claim 3 , polyepoxy ethers claim 3 , divinyl sulfone (DVS) claim 3 , genipin claim 3 , polyaldehyde and diphenylphosphoryl azide (DPPA) claim 3 , genipin claim 3 , epoxy compounds claim 3 , dialdehyde starch claim 3 , glutaraldehyde claim 3 , formaldehyde claim 3 , dimethyl suberimidate claim 3 , carbodiimides claim 3 , succinimidyls claim 3 , diisocyanates claim 3 , and acyl azide; or any combination thereof.5. The acellular adipose biocompatible biomaterial composition of claim 1 , further comprising a biopolymer scaffold.6. The composition of claim 5 , wherein the acellular adipose biocompatible biomaterial and biopolymer scaffold further comprise a biopolymer cross-linking agent.7. The acellular adipose biocompatible biomaterial ...

Non-enzymatic method and milling device

Non-enzymatic method and milling device for preparing therapeutic cells from adipose tissue comprising: continuously feeding the adipose tissue to the milling device ( 2 ); mechanically separating the cells or cell aggregates from adipose tissue moving through the milling device ( 2 ) by means of a multiplicity of blades ( 19 ) of a rotor ( 10 ), wherein the blades ( 19 ) are arranged in a spaced arrangement with respect to the overall direction of flow and the blades ( 19 ) are moving about an axis of rotation ( 18 ), wherein the axis of rotation ( 18 ) is provided essentially parallel to said overall direction of flow; continuously withdrawing the processed tissue comprising the separated cells from the milling device ( 2 ).

APPLICATIONS OF BUTYLIDENEPHTHALIDE

Applications of butylidenephthalide (BP), comprising the use of BP in providing a kit for promoting differentiation of stem cells into brown adipose cells, and the use of BP in preparing a medicament, wherein the medicament is used for inhibiting the accumulation of white adipose cells, promoting the conversion of white adipose cells into brown adipose cells, inhibiting weight gain and/or reducing the content of triglycerides, glucose, and total cholesterol in blood. 1. A kit for promoting the differentiation of a stem cell into a brown-like adipose cell , comprising the following components:(1) a conditional medium, comprising a basic medium and an ingredient capable of inducing the differentiation of a stem cell into an adipose cell; and(2) butylidenephthalide (BP).2. The kit as claimed in claim 1 , wherein the ingredient is selected from the group consisting of rosiglitazone claim 1 , insulin claim 1 , 3-isobutyl-1-methylxanthine (IBMX) claim 1 , dexamethasone claim 1 , and combinations thereof.3. A method for inhibiting the accumulation of white fat and/or promoting the conversion of white fat into brown fat claim 1 , comprising administering to a subject in need an effective amount of butylidenephthalide (BP).4. A method for inhibiting the accumulation of white fat claim 1 , promoting the conversion of white fat into brown fat claim 1 , inhibiting weight gain and/or reducing the contents of triglycerides claim 1 , glucose and total cholesterol in blood claim 1 , comprising administering to a subject in need an effective amount of butylidenephthalide (BP) claim 1 , and the butylidenephthalide (BP) is administered with at least one of a mesenchymal stem cell and a brown-like adipose cell.5. The method as claimed in claim 4 , which is for anti-obesity and/or preventing metabolic syndrome associated with obesity.6. The method as claimed in claim 5 , wherein the metabolic syndrome is at least one of diabetes mellitus claim 5 , cerebrovascular disease claim 5 , ...

MICRORNA AND USES IN BROWN FAT DIFFERENTIATION

This invention reveals a novel miRNA and a novel miRNA-regulated signaling network which controls brown adipogenesis and thermogenic programs, thereby providing a powerful approach for the treatment of obesity and related metabolic diseases. In this regard, the present invention is also directed towards methods of treatment of obesity and excess weight (overweight) and metabolic disorders caused by or aggravated by a subject being overweight or obese. 1. A method of regulating Brown Adipose Tissue (BAT) activation and differentiation in a subject , the method comprising contacting one or more cells in the subject with a composition comprising one or more exogenous miRNA-455 selected from the group consisting of [SEQ ID NOs: 1-4] , the cells being selected from the group consisting of brown adipose cells , white adipose cells and preadipocytes.2. The method of claim 1 , wherein the upregulation of BAT comprises increasing the thermogenic activity of BAT.3. The method of claim 1 , wherein the upregulation of BAT comprises increasing the amount of BAT in the subject.4. The method of claim 1 , wherein said subject is overweight or obese.5. The method of claim 1 , wherein said subject has diabetes.6. The method of claim 5 , wherein said diabetes is selected from type 1 and type 2 diabetes.7. The method of claim 1 , wherein said composition comprising exogenous miRNA-455 additionally comprises a pharmacologically acceptable carrier.8. A method of regulating one or more of Brown Adipose Tissue (BAT) activity and differentiation claim 1 , the method comprising contacting one or more cells selected from brown adipose cells claim 1 , white adipose cells and preadipocytes with an agent that inhibits at least partially one or more of HIF1an claim 1 , Rux1+1 and necdin.9. The method of claim 8 , wherein said inhibitor is Clioquinol (CQ: Iodochlorhydroxyquin or 5-chloro-7-iodo-8-hydroxyquinoline).10. A method of treating obesity in a subject claim 8 , the method comprising ...

ADIPOSE TISSUE COMBINATIONS, DEVICES, AND USES THEROF

Described are devices, systems, and methods for processing adipose tissue for reintroduction into a body. In some embodiments, adipose tissue is mixed with an additive prior to reintroduction. 1. A system for preparing an adipose composition for reintroduction into a body , the system having a container that comprises:a first compartment positioned at a top vertical level and configured to receive a harvested adipose tissue;a second compartment positioned below the first compartment comprising a port fluidly connecting the second compartment to the first compartment;a third compartment positioned at a bottom level comprising an outlet configured to allow removal of the adipose composition for reintroduction into the body; anda tortuous path having a plurality of sharp turns, the tortuous path fluidly connecting the second compartment to an outlet in the third compartment.2. The system of claim 1 , further comprising an additional compartment positioned at an intermediate vertical level between the second and third compartments claim 1 , wherein the additional compartment includes the tortuous path.3. The system of claim 1 , wherein process of the harvested adipose tissue in the first compartment comprises one that separates adipocytes claim 1 , regenerative cells claim 1 , or a combination thereof in the harvested adipose tissue from unwanted fluids and materials.4. The system of claim 1 , wherein the port connecting the second compartment to the first compartment comprises a filter.5. The system of claim 1 , wherein the second compartment comprises an eruptable pouch containing an additive for combining with a processed harvested adipose tissue or an injection port configured to receive an additive for combining with a processed harvested adipose tissue.6. The system of claim 5 , wherein the additive comprises a hydrogel claim 5 , a hyaluronic acid claim 5 , a collagen claim 5 , a hyaluronic acid crosslinked to a collagen claim 5 , or a combination thereof.7. The ...

TM4SF19 AS MARKER FOR DIAGNOSING OBESITY AND METHOD USING SAME

The diagnosis of obesity can be effectively carried out by using a composition for diagnosing obesity comprising a substance, which specifically couples to TM4SF19, a kit, and a method for diagnosing the obesity using the same. In addition, a candidate substance capable of treating obesity can be effectively screened in accordance with a method for screening a candidate substance for treating obesity, which inhibits the TM4SF19. 1. A composition for diagnosing obesity , comprising an antibody , an antigen binding fragment , or a polypeptide specifically binding to a TM4SF19 protein or a fragment thereof , or a probe , a primer set , or a nucleotide specifically binding to a nucleotide sequence encoding the TM4SF19 protein.2. The composition of claim 1 , wherein the TM4SF19 protein comprises any one sequence of SEQ ID NOS: 5 to 8 claim 1 , and the nucleotide sequence encoding the TM4SF19 protein comprises any one sequence of SEQ ID NOS: 1 to 4.3. The composition of claim 1 , wherein the antibody claim 1 , the antigen binding fragment claim 1 , or the polypeptide binds to a transmembrane domain d of TM4SF19 and/or a linker region thereof.4. A kit for diagnosing obesity claim 1 , comprising the composition of and a reagent for detecting the composition.5. A method claim 1 , comprising measuring an expression level of TM4SF19 from a complex claim 1 ,wherein the complex is formed by contacting a sample separated from a subject with an antibody, a peptide, or a protein specifically binding to a TM4SF19 protein or a fragment thereof, or a combination thereof, or a probe, a primer, or a nucleotide specifically binding to a nucleotide sequence encoding the TM4SF19 protein, or a combination thereof.6. The method of claim 5 , wherein the measuring of the expression level is performed by at least one method selected from the group consisting of RT-PCR claim 5 , RNase protection assay (RPA) claim 5 , Northern blotting claim 5 , and a DNA chip.7. The method of claim 5 , wherein ...

YARN FOR CELL CULTURE SCAFFOLD, AND FABRIC INCLUDING THE SAME FOR CELL CULTURE SCAFFOLD

Provided is yarn for a cell culture scaffold. The yarn includes ply-twisted fiber strands, and to prevent density-dependent inhibition of cultured cells and increase a cell-contacting specific surface area, at least a part of the plurality of twisted fiber strands are untwisted such that an open space is formed between the fibers. A cell proliferation rate and cell viability may be increased by creating microenvironments suitable for migration, proliferation and differentiation of the cultured cells using the yarn. A large quantity of cells may be simultaneously cultured by creating a cell proliferation space as large as possible in a scaffold space having a limited cell proliferation space, and cell proliferation may be steadily maintained by preventing the inhibition of cell proliferation due to intercellular contact. The cells cultured may be cultured to have a shape/structure suitable for application to an in vitro experiment model or implantation into an animal body. 1. Yarn for a cell culture scaffold , comprising:a ply-twisted fiber strands; andan open space between fibers by untwisting at least a part of the ply-twisted fiber strands to prevent density-dependent inhibition of cells to be cultured and increase a cell-contacting specific surface area.2. The yarn according to claim 1 , wherein the fiber is spun yarn claim 1 , filament yarn or slitting yarn.3. The yarn according to claim 1 , wherein the fiber includes claim 1 , as a fiber-forming component claim 1 , any one or more non-biodegradable components selected from the group consisting of polystyrene (PS) claim 1 , polyethylene terephthalate (PET) claim 1 , polyethersulfone (PES) claim 1 , polyvinylidene fluoride (PVDF) claim 1 , polyacrylonitrile (PAN) claim 1 , polydimethylsiloxane (PDMS) claim 1 , a polyamide claim 1 , a polyalkylene claim 1 , a poly(alkylene oxide) claim 1 , a poly(amino acid) claim 1 , a poly(allylamine) claim 1 , polyphosphazene and a polyethyleneoxide-polypropyleneoxide block ...

METHOD FOR ISOLATING STROMAL VASCULAR FRACTION

Disclosed is a method for recovering stromal vascular fraction from a sample. The method comprises providing a mechanical force capable of breaking the sample into a single cell suspension whilst maintaining intact stromal vascular fraction cells cellular structures, wherein the mechanical force is mincing and/or homogenization. Also disclosed are methods of using the stromal vascular fraction. 1. A method for recovering stromal vascular fraction from a sample , the method comprising providing a mechanical force capable of breaking the sample into a single cell suspension whilst maintaining intact stromal vascular fraction cells cellular structures , wherein the mechanical force is mincing and/or homogenization , wherein the method is a non-enzymatic digestion.2. The method according to claim 1 , wherein the sample is an adipose tissue.3. The method according to claim 1 , wherein the method further comprises the step of isolating the stromal vascular fraction from the single cell suspension.4. The method according to claim 3 , wherein the step of isolating the stromal vascular fraction is performed by density gradient claim 3 , flow cytometry claim 3 , membrane filtration claim 3 , membrane adsorption or centrifugation.5. The method according to claim 1 , wherein the stromal vascular fraction comprises any one of the following cells: adipose-derived stem cells claim 1 , mesenchymal cells claim 1 , hematopoietic cells claim 1 , hematopoietic stem/progenitor cells claim 1 , chondrocytes claim 1 , osteoblasts claim 1 , osteoclasts claim 1 , endothelial precursor or progenitor cells claim 1 , endothelial cells claim 1 , smooth muscle cells claim 1 , pericytes claim 1 , CD34+ cells claim 1 , CD29+ cells claim 1 , CD166+ cells claim 1 , Thy-1+ or CD90+ stem cells claim 1 , CD44+ cells and immune cells selected from the group consisting of monocytes claim 1 , leukocytes claim 1 , lymphocytes claim 1 , B and T cells claim 1 , NK cells claim 1 , macrophages claim 1 , ...

ADIPOSE STROMAL VASCULAR FRACTION-CONDITIONED MEDIUM

A combination of therapeutic factors derived from non-adherent or poorly adherent stromal vascular fraction (SVF) cells exposed to protein-free basal medium are disclosed. 1. A conditioned medium obtained from digested adipose tissue.2. The conditioned medium of claim 1 , wherein the digested adipose tissue is a fractioned adipose tissue.3. The conditioned medium of claim 2 , wherein the fractioned adipose tissue is selected from the group consisting of adipose-derived stem cells and non-adipocyte claim 2 , stromal-vascular fraction.4. A conditioned medium obtained from a non-adipocyte claim 2 , stromal-vascular fraction.5. The conditioned medium of claim 4 , wherein the conditioned medium is obtained from a suspension culture of the non-adipocyte claim 4 , stromal-vascular fraction.6. The conditioned medium of claim 4 , wherein the non-adipocyte claim 4 , stromal-vascular fraction comprises at least one of a leukocyte and an endothelial cell.7. A method of producing conditioned medium claim 4 , the method comprising: digesting adipose tissue by contacting the adipose tissue with an enzyme; fractionating the adipose tissue to obtain a fractionated adipose tissue that comprises at least a stromal-vascular fraction; culturing cells obtained from the fractionated tissue in a culture medium; and separating the cells from the culture medium to produce the conditioned medium.8. The method of claim 7 , cells obtained from the stromal-vascular fraction are cultured in the culturing step.9. The method of claim 8 , wherein the stromal-vascular fraction is selected from the group consisting of a freshly isolated population of stromal-vascular fraction and a non-adherent population of stromal-vascular fraction.10. The method of claim 7 , further comprising culturing cells from digested adipose tissue after the digesting step for a sufficient time to allow a plurality of cells to adhere to a culture substrate; collecting non-adherent cells; culturing the non-adherent cells; and ...

Method for promoting adipocyte differentiation and obesity-related disease treatment

Here we show that epigenetic control of Neuregulin-1 (NRG1) affects adipose differentiation of stem cells in vitro. Building on this finding, we established a model in which NRG1 is a white adipose tissue (WAT) specific regulator analogous to the role of NRG4 in black adipose tissue (BAT). In this light, NRG1 functions in a paracrine or autocrine manner to regulate formation of new adipocytes from stem populations, both in vitro and in vivo. In neurons, NRG1 has been shown already to play a similar role, promoting neuronal cell differentiation from progenitors in the vertebrate cortex and retina and even promoting neuronal differentiation in vitro. Similarly, in the heart, NRG1 promotes differentiation of cardiomyocytes from their stem cell progenitors both in vivo and in vitro and for this reason has been successfully tested in clinical trials for heart failure. Our model extends these findings to adipose biology and indicates that epigenetic control of NRG1 may constitute an intrinsic mechanism limiting the expansion of WAT depots, potentially elucidating important health implications for the comorbidities of obesity and providing treatment for obesity-related diseases.

TISSUE PROCESSING DEVICE AND ASSOCIATED SYSTEMS AND METHODS

Tissue processing devices are provided. The tissue processing devices can be used to process and transport tissue in a closed and continuous environment. The devices can be used for adipose tissue transfer, including autologous fat grafting. 1. A tissue processing device , comprising:a body including a cavity formed therein, the body defining a proximal section and a distal section;a tissue collection port formed in a wall of the body and adapted to receive tissue therethrough and in fluid communication with the cavity;an auger including a helical blade within the cavity for transferring the tissue from the proximal section to the distal section of the body;a filter separating the cavity to define a first cylindrical compartment and a second compartment, wherein the filter defines at least a portion of a wall surrounding the auger; andan extrusion port formed in a wall of the body and adapted for removal therethrough of the tissue from the cavity.2. The tissue processing device of claim 1 , wherein the tissue collection port and the extrusion port are in fluid communication with the first cylindrical compartment.3. The tissue processing device of claim 1 , comprising at least one injection port formed in fluid communication with the cavity and adapted for injection of a wash solution therethrough.4. The tissue processing device of claim 1 , comprising a vacuum port formed in the wall of the body claim 1 , the vacuum port being in fluid communication with the second compartment.5. The tissue processing device of claim 1 , comprising a crank for rotatably driving the auger.6. The tissue processing device of claim 1 , comprising an automated actuation unit for rotatably driving the auger.7. The tissue processing device of claim 6 , wherein the automated actuation unit comprises:a graphical user interface connected to a computer or at least one processor; anda motor configured to receive input regarding information related to actuation of the auger.8. The tissue ...

Human brown adipose derived stem cells and uses

An isolated human brown adipose tissue stem cell line. In one embodiment, the isolated human brown adipose tissue stem cell line expresses the markers CD9, SSEA4, CD44, CD90, CD166, CD73, but not CD14, CD34, CD45 or STRO-1. In another embodiment, the isolated human brown adipose tissue stem cell line expresses the genes UCP1, PPARGC1A, NRF1, FOXC2, CREB1, SIRT3, and WNT5A (REFX). In still another embodiment, the isolated human brown adipose tissue stem cell line is capable of differentiating into osteoblasts, chondrocytes, and adipocytes.